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All under heaven realizing beauty as beauty, wickedness already. 
All realizing goodness as goodness, no goodness already. 
Hence existence and nothing give birth to one another, 
Difficult and easy become one another, 
Long and short form one another, 
High and low incline one another, 
Sound and tone blend with one another, 
Front and back follow one another. 
That is forever. 
                            -- Tao Te Ching, Laozi 
 
    Like that, Candida albicans is a friend of humans, as well as an enemy! 
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Summary 
Candida albicans is a common opportunistic fungal pathogen, which normally 
resides on mucosal surfaces of healthy individuals as a harmless commensal. 
However, in immunocompromised and critically ill patients, the inability to control 
colonizing C. albicans on mucosal surfaces can lead to superficial infections and 
even disseminated candidemia. This severe Candida albicans infection is usually 
associated with a high mortality of up to 46%-75% in infected populations. So far the 
diagnosis of Candida infections remains difficult. 
During infection, C. albicans undergoes a yeast-to-hypha transition and 
secretes numerous proteins for invasion of host tissues and modulation of the 
immune response. It is assumed that mainly the hyphal form is associated with the 
invasive phenotype of C. albicans and transition from colonization to infection is 
accompanied with a yeast-to-hypha transition. Hence, it is particularly interesting to 
investigate the dynamic changes of extracellular proteins during the yeast-to-hypha 
transition. Still little is known about the interplay of C. albicans extracellular proteins 
with the host humoral immunity. Investigation of the extracellular protein antigens of 
C. albicans could therefore give new insights into this question and help search for 
novel biomarker candidates for diagnosis of C. albicans infections. 
Here, we combined 2D gel- and LC-MS/MS-based approaches for 
characterization of the dynamic changes of the C. albicans secretome during yeast-
to-hypha transition. In order to meet the large demand of protein amount for 2D-GE 
analysis, we set up a workflow for the cultivation of C. albicans yeast and hyphal cells 
in a batch-fermenter. The combination of both techniques led to a more 
comprehensive C. albicans secretome map. A total of 101 extracellular yeast proteins 
and 410 extracellular hyphal proteins were identified. Among them, 65 proteins were 
shared by both cell morphologies, while 36 proteins were exclusively detected in 
yeast and 345 only in hyphal cells. Both C. albicans yeast and hyphal secretomes 
mainly consist of cell wall-associated proteins, proteins in response to environmental 
stimuli, secreted proteases, lipases and adhesins and carbohydrate metabolism-
associated proteins. Besides extracellular proteins, intracellularly processed peptides 
in the supernatant of Candida hyphal culture were also investigated. Ece1p turned 
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out to be the most abundant intracellular processed protein in the culture 
supernatant. Intriguingly, the Ece1p-III peptide was identified as the first fungal 
cytolytic peptide toxin. It can damage epithelial membranes directly and trigger a 
danger response pathway to activate epithelial immunity. In addition, the fasciclin 
domain-containing protein CaO19.3004, which has a domain with repeated KR sites 
similar to Ece1p and a conserved cell adhesion domain (Fas-domain), was found to 
be another abundant, proteolytically processed protein. 
Further, we focused on the serological responses of the host to C. albicans 
extracellular proteins. In mice systemically infected with C. albicans, the serological 
responses to the secreted proteins of C. albicans yeast cells were less pronounced 
and diverse in comparison to humans. An in-depth investigation of the serological 
response of candidemia patients to extracellular proteins of C. albicans was 
conducted by a 2D-immunoblotting approach combined with mass spectrometry for 
protein identification. Based on the screening of sera from candidemia patients and 
three control groups (systemic inflammatory response syndrome, bacteremia patients 
and healthy controls) a core set of 20 immunodominant anti-C. albicans extracellular 
protein antibodies was identified, seven of which represent potential diagnostic 
markers for candidemia (Xog1p, Rot2p, Eno1p, Met6p, Tsa1p, Tpi1p and Prx1p). 
Intriguingly, some secreted, strongly glycosylated protein antigens showed high 
cross-reactivity with sera from non-candidemia control groups. Enzymatic 
deglycosylation of hyphal secreted proteins significantly impaired sera antibody 
recognition. In addition, deglycosylation of the recombinantly produced, secreted 
aspartyl protease Sap6p confirmed a significant contribution of glycan epitopes to the 
recognition of Sap6p by serum antibodies of patients.  
In summary, this study provides new insights into the serological response of 
candidemia patients to extracellular proteins of C. albicans yeast and hyphal cells. 
Seven C. albicans extracellular antigens were identified as promising diagnostic 
biomarker candidates for the diagnosis and prognosis of candidemia. In particularly, 
the mechanism underlying the high cross-reactivities of C. albicans extracellular 
antigens was elucidated. As shown here, glycosylation of C. albicans extracellular 
proteins enhanced the immunogenicity of glycopeptide epitopes and also led to 
relatively unspecific binding of antibodies, resulting in cross-reactivity of C. albicans 
protein antigens. 
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Kurzzusammenfassung 
Candida albicans ist ein häufig vorkommender, opportunistisch human 
pathogener Hefepilz bei Menschen. Er besiedelt normalerweise als kommensaler 
Organismus der mikrobiellen Flora die Schleimhäute vieler gesunden Menschen. 
Geht jedoch die immunologische Kontrolle über die Besiedlung der Mucosa durch 
C. albicans in immunsupprimierten oder schwerkrankenden Patienten verloren, kann 
C. albicans Oberflächeninfektionen, aber auch lebensbedrohliche, systemische 
Infektionen verursachen. Systemische Infektion gehen meist mit hoher Sterblichkeit 
von 46% bis 75% in infizierten Populationen einher. Bisher ist die Diagnose einer 
C. albicans-Infektion schwierig und häufig nicht eindeutig. 
Während der Infektion ändert C. albicans seine Morphologie von der Hefe- in 
die Hyphenform und scheidet zahlreiche Proteine zur Invasion des Wirtsgewebes 
und zur Modulation der Immunreaktion aus. Noch wenig ist über die Wechselwirkung 
zwischen extrazellulären Proteinen von C. albicans und der humoralen 
Immunantwort des Wirts bekannt. Deshalb war es besonders interessant, die 
extrazellulären Proteinantigene von C. albicans zu untersuchen und nach neuen 
Biomarkerkandidaten für die Diagnose von Candida-Infektionen zu suchen. 
In dieser Arbeit wurden 2D Gel- und LC-MS/MS-basierte proteomische 
Methoden verwendet, um die dynamische Veränderung des Sekretoms von 
C. albicans während der morphologischen Umwandlung von Hefe- zu Hyphenzellen 
zu untersuchen. Dies führte zu einer umfassenden Charakterisierung des C. albicans 
Sekretoms. Insgesamt wurden 101 extrazelluläre Hefeproteine und 410 extrazelluläre 
Hyphenproteine identifiziert. Unter ihnen befanden sich 65 Proteine, die in beiden 
Zellmorphologien gefunden wurden, während 36 Proteine nur in Hefe- und 345 
ausschließlich in Hyphezellen detektiert wurden. Wegen des Bedarfs an größeren 
Proteinmengen wurde die Kultivierung von C. albicans Hefe- und Hyphezellen in 
einem Fermenter etabiliert. Außerdem wurden auch sekretierte, intrazellulär 
prozessierte Peptide im Kulturüberstand von C. albicans Hyphenkulturen untersucht. 
Interessanterweise wurde ein Peptid, das Ece1p-III, identifiziert, welches als erstes 
zelllytische Pilzpeptidtoxin beschrieben wurde. Es zerstört die Epithelmembran des 
Wirtes und aktiviert die Epithelimmunität. Zusätzlich wurde Peptide des 
uncharakterisierten Proteins CaO19.3004 in größeren Menge im Überstand 
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nachgewiesen. Dessen Proteinsequenz enthält eine Fasciclin-Domaine und repetitive 
KR-Elemente ähnlich wie beim Ece1p Protein. 
Im Weiteren fokussierte sich die Arbeit auf die serologischen Antworten des 
Wirts auf extrazelluläre Proteine von C. albicans. In systemisch, mit C. albicans 
infizierten Mäusen waren die serologischen Antworten auf sezernierte Proteine von 
C. albicans Hefezellen weniger ausgeprägt und vielfältig im Vergleich zur Antwort bei 
Menschen.  
Des Weiteren wurde eine eingehende Untersuchung der serologischen 
Reaktionen von Candidämie-Patienten auf extrazelluläre Proteine von C. albicans 
durchgeführt. Zu diesem Zweck wurde ein 2D-Immunoblot Ansatz mit anschließender 
massenspektrometrischer Identifizierung von Proteinen verwendet. Basierend auf 
dem Screening von Seren von Candidämie-Patienten und drei Kontrollgruppen 
(Systemisches inflammatorisches Response-Syndrom, Bakteriämie und gesunde 
Probanden) wurden 20 immundominante, extrazelluläre Proteine identifiziert, wobei 
aus dieser Gruppe sieben Proteine potentielle diagnostische Marker für den 
Nachweis einer invasiven Candidämie darstellen (Xog1p, Rot2p, Eno1p, Met6p, 
Tsa1p, Tpi1p und Prx1p). Interessanterweise zeigten einige sekretierte, stark 
glykosylierte Proteinantigene hohe Kreuzreaktivitäten mit Seren aus Kontrollgruppen 
ohne Candida Infektion. Die Antikörpererkennung von Proteinen, die aus C. albicans 
Hyphezellen stammte, wurde nach enzymatischer Deglykosylierung erhebllich 
vermindert. Weiterhin bestätigte die enzymatische Deglykosylierung der rekombinant 
hergestellten, sekretierten Aspartylprotease Sap6p, dass Glycan-Epitope einen 
signifikanten Beitrag zur Erkennung von Sap6p durch Antikörper aus Patientenseren 
leisten. 
Zusammenfassend liefert diese Studie neue Erkenntnisse über die 
serologische Reaktion von Candidämie-Patienten auf extrazelluläre Proteine des 
Hefepilzes C. albicans und seiner beiden morphologischen Wachstumsformen, Hefe- 
und Hyphezellen. Sieben extrazelluläre Antigene von C. albicans wurden als 
vielversprechende Biomarker Kandidaten zur Diagnose und Prognose von 
Candidämien identifiziert. Wie in dieser Arbeit gezeigt wurde, verstärkt die 
Glykosylierung extrazellulärer Proteine der Hefe C. albicans die Immunogenität und 
begünstigt zudem die unspezifische Bindung von Anti-Glykan Antikörpern, was zu 
Kreuzreaktivität mit Proteinantigenen von C. albicans führen kann. 
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Introduction 
1 The human pathogenic fungus Candida albicans 
Candida albicans is a common fungal pathogen of humans, which can cause 
systemic, life-threatening infections. It is capable of growing as unicellular budding 
yeast cells, filamentous hyphae or pseudohyphae, which is termed polymorphism. 
There is no known soil life cycle for C. albicans as described for other fungi with a 
saprophytic lifestyle, such as Aspergillus fumigatus, Histoplasma capsulatum and 
Paracoccidioides brasiliensis (Klein et al. 2007; Gow et al. 2012). Instead, the natural 
ecological niche of C. albicans is the mammalian host, where it is primarily 
associated with the gastrointestinal tract. 
Among the human pathogenic fungi, C. albicans is the most common cause of 
nosocomial bloodstream infections (Perlroth et al. 2007). In up to 70% of healthy 
individuals, C. albicans colonizes the mucosal surfaces as a commensal, such as 
genital and gastrointestinal mucosa (Gow et al. 2002; Casadevall et al. 2003; Saville 
et al. 2003; Wächtler et al. 2011; Gow et al. 2012). However individuals, lacking a 
proper immune response, are predisposed to superficial candidiasis of the oral or 
vaginal mycosal surface and under certain circumstances even to life-threatening 
disseminated candidemia, especially among immunocompromised patients. It has 
been reported that 50 to 75% of women in their childbearing years suffer from at least 
one episode of vulvovaginitis, and 5 to 8% have at least four episodes annually 
(Sobel 2007; Brown et al. 2012). In the US, the frequency of disseminated 
candidiasis was approximately 24 cases per 100,000 individuals in a year (Wilson et 
al. 2002; Perlroth et al. 2007). A very high mortality rate of up to 40% is often 
associated with systemic candidiasis (Alonso-Valle et al. 2003; Gudlaugsson et al. 
2003; Pappas et al. 2003; Perlroth et al. 2007). 
An intriguing trait of C. albicans is that this fungus is able to adapt to a 
diversity of host niches as a benign member of the microbial flora. However it can 
also infect host niches by the means of a wide range of virulence factors and fitness 
attributes. They include the morphological transition between yeast and hyphal form, 
the expression of adhesins and invasins, thigmotropism, the secretion of hydrolytic 
enzymes and the formation of biofilms (Mayer et al. 2013). During infection, yeast 
cells initiate hypha formation on epithelial cell surfaces (Figure 1). They penetrate 
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and invade the epithelium, once their filaments grow through the epithelial tissue and 
penetrate into blood vessels, where they switch back to yeast cells, disseminate with 
the bloodstream, adhere to endothelial cells again and penetrate into the organs 
nearby (Figure 1C).         
 
Figure 1 A) Electron microscopic image of C. albicans cells colonizing the oral 
mucosa. B) Electron microscopic image of a C. albicans hyphal filament penetrating 
through the oral mucosa. Photographs A and B courtesy: Holland/Özel, RKI. C) 
C. albicans tissue invasion. This picture is modified from Nat. Rev. Microbiol. 2012, 
Gow et al. 
Since C. albicans lives as a commensal in the host, it is difficult to distinguish 
the infectious from the harmless commensal form during the diagnosis of a Candida 
infection. Still, there is lack of efficient and reliable diagnostic biomarkers for 
C. albicans. Until now, the blood culture is still the gold standard for the identification 
of systemic Candida infection in the clinics. In fact, the frequency of disseminated 
candidiasis is markedly underestimated with a proven positive blood culture as a 
single diagnostic criterion. Past autopsy studies and more recent clinical 
investigations showed that 30-50% of patients with disseminated candidiasis had 
negative blood cultures (Berenguer et al. 1993; Kami et al. 2002; Perlroth et al. 
2007). To improve the early diagnosis of Candida infections, newer non-culture-
based assays have been investigated as a tool for the detection of diagnostic 
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biomarkers, e.g. the antigens mannan, L/D-arabinitol, ß-glucan (Ostrosky-Zeichner 
2012). According to the sensitivity and specificity the superior biomarkers are ß-1,3-
D-glucan and mannan antigens (Held et al. 2013). However, they are still far from 
being efficient for a reliable diagnosis. Many factors can lead to false-positive results, 
such as contamination with fungal components in the albumin preparations or 
hemodialysis with cellulose membranes, which mimic the structure of ß-glucans 
(Ostrosky-Zeichner 2012). Therefore novel diagnostic Candida-specific antigens are 
still strongly needed.  
For the efficient treatment of disseminated candidiasis, an early initiation of an 
effective antifungal therapy is crucial (Perlroth et al. 2007). In non-neutropenic 
patients fluconazole is a standard antifungal compound for disseminated candidiasis. 
However fluconazole is not efficient to treat C. glabrata infections, so antifungals with 
a broader spectrum of activity such as echinocandins (Caspofungin, Anidulafungin) 
or the triazole voriconazole are preferred. Nevertheless, the mortality of disseminated 
candidiasis is still high, and new therapeutic and preventative strategies are badly 
needed (Perlroth et al. 2007). In human host, extracellular proteins of C. albicans 
directly exposed to immune cells and also interacted with them.  
 
2. Extracellular proteins of C. albicans 
2.1 Classical secretory pathway in fungi 
In fungi, like C. albicans, most secreted proteins enter the lumen of the rough 
endoplasmic reticulum as the first organelle of the secretory pathway via an N-
terminal hydrophobic signal peptide. There, the secretory proteins are properly folded 
and post-translationally modified. Misfolded or incorrectly modified proteins are 
delivered to proteasomes (Hampton 2002) or vacuoles (Coughlan et al. 2004) for 
degradation. After the quality control of extracellular proteins, those who are properly 
folded are translocated to the Golgi complex, where they are further modified and 
packed in vesicles for the transport to the cell surface or secretion to the outer space. 
Vacuolar proteins, which are also sorted in the Golgi apparatus, are delivered to 
vacuoles via endosomes. In filamentous-growing fungi, the Golgi apparatus is often 
found at the apical regions of hyphae (Cole et al. 2000; Kuratsu et al. 2007), which 
supports the hypothesis that protein secretion mainly occurs at hyphal apices. 
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Transmembrane proteins and glycosylphosphatidylinositol (GPI)-anchored proteins 
are retained in the cell membrane or moved further to the cell wall and are covalently 
attached to glucans via a truncated GPI anchor (GPI-proteins) (Klis et al. 2002; Sorgo 
et al. 2013). The soluble secreted proteins are either continuously released 
(constitutive secretory pathway) or stored in granules for rapid discharge after certain 
stimulation (regulated secretory pathway) (Halban et al. 1994). 
 
2.2 Nonconventional secretory pathways in fungi 
During the past decade using the two yeast model organisms S. cerevisiae 
and C. albicans, more and more evidences of nonconventional secretory pathways 
have been provided by morphological, biochemical and genetic studies. They are 
comprehensively reviewed in Nombela et al. (2006). It could be clearly shown that 
many proteins lacking an N-terminal signal peptide reach the cell surface and 
extracellular milieu. These proteins are mainly involved in the cell-wall structure and 
dynamics, and interactions with host components. 
Several non-conventional secretory pathways have been described in 
S. cerevisiae and C. albicans, which were comprehensively reviewed by LaJean 
Chaffin (Nombela et al. 2006; Chaffin 2008). In short, ScSTE6 encodes an ATP-
binding cassette transporter that specifically exports the peptide pheromone ɑ-factor 
(Magee et al. 2002). The nonclassical export genes NCE101 and NCE102 are able 
to export the mammalian nonclassical substrate galectin-1, when it is expressed in 
yeast (Cleves et al. 1996). Endosome recycling is also proposed for the return of 
S. cerevisiae Ste3p back to the plasma membrane. This protein represents a 
classically exported a-factor pheromone receptor (Chen et al. 2000). Another 
postulated pathway of unconventional protein secretion is membrane blebbing, which 
involves the formation of exosomes on the outer surface of the cell, and membrane 
flip-flop, which describes a direct translocation across the plasma membrane (Nickel 
2003). Other routes include substrate-specific interactions of helper proteins with the 
secreted proteins (FGF-1, IL-1ɑ) (Prudovsky et al. 2003; Rajalingam et al. 2007; 
Rodrigues et al. 2008). Recently, extracellular vesicles with cytosolic proteins have 
been isolated from C. albicans and Cryptococcus neoformans (Rodrigues et al. 2008; 
Gil-Bona et al. 2015). Whatever mechanism underlies the nonconventional secretion, 
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they all directly or indirectly play a role in the interaction between the fungus and its 
host. 
 
2.3 Proteolytic processing in the secretory pathway 
In the late secretory pathway of eukaryotic cells, proteolytic processing is a 
major form of post translational modification, reviewed in Zhou et al. (1999). Many 
proteins are synthesized as inactive precursors. They may be called proproteins or 
zymogens in case of enzymes. After proteolytic processing these proproteins are 
activated. The process is often carried out by serine proteases, which remove a 
peptide segment from either end of the target protein or cleave internal bonds of the 
protein that lead to major changes in the structure and function of the protein. In 
yeast this process is very crucial for the activation, inhibition or destruction of 
numerous enzymes and peptide hormones (Bader et al. 2008). In mammals, many 
cellular processes are regulated by this process, like gene expression (Sakai et al. 
1998), embryogenesis (Dubois et al. 1995; Cui et al. 1998; Peschon et al. 1998; 
Roebroek et al. 1998), the cell cycle (Zhou et al. 1999), programmed cell death 
(Thornberry et al. 1998) and endocrine/neural functions (Zhou et al. 1999). 
The proteolysis is mainly mediated by calcium-dependent serine 
endoproteases. They are related to yeast subtilisin proteases (Steiner et al. 1992; 
Zhou et al. 1999). Therefore they are also called Subtilisin-like Proprotein 
Convertases (SPCs) or PCs. In mammals, the SPCs family consists of seven 
members (Seidah et al. 2006), while fungi harbor only a single gene, which encodes 
for a subtilisin-like serine proteinase and is designated as KEX2 (Bader et al. 2008). 
The phenotypes of KEX2 deletion mutants have been reported from many fungi, 
such as S. cerevisiae (Wickner 1974), P. pastoris (Werten et al. 2005), C. albicans 
(Newport et al. 1997; Newport et al. 2003), C. glabrata (Bader et al. 2001), 
Schizosaccharomyces pombe (Ladds et al. 2000), Aspergillus nidulans (Punt et al. 
2003). These characteristics include morphological changes and reduced virulence in 
C. albicans (Newport et al. 2003), hypersensitivity to antimycotic drugs in C. glabrata 
and inviability in S. pombe (Ladds et al. 2000; Bader et al. 2001). In general, fungal 
Kex2p proteases recognize specific lysine-arginine or arginine-arginine motifs in their 
substrate proteins. However, the structural features and the amino acids surrounding 
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the processing site contribute to the recognition as well (Bader et al. 2008). Besides a 
few well-known substrates of fungal Kex2p, such as α-pheromone precursors, killer 
toxin precursors and aspartic protease propeptides, some new substrates were found 
in C. albicans: The protein CaEce1, the uncharacterized CA0365, one member of the 
Pry protein family and a group of CaOps4-like proteins (Bader et al. 2008).  
 
2.4 The cell wall proteins of C. albicans 
The cell wall proteins of C. albicans are often released into the medium during 
growth (Sorgo et al. 2010). The cell wall of C. albicans is characterized by two 
distinguished layers. The out layer is composed of glycoproteins associated with 
mannan, while the inner layer consists of cross-linked polysaccharides, mainly 
including chitin, ß-1,6-glucan and ß-1,3-glucan (Figure 2).  
  
Cell wall proteins can be categorized into covalently attached proteins and 
non-covalently attached proteins. GPI-anchored proteins and Pir proteins (proteins 
with internal repeats) are the most abundant covalently attached protein classes. 
GPI-CWPs are linked to ß-1,6-glucan through a glycophosphatidylinositol remnant, 
whereas Pir proteins are directly linked to cell wall ß-1,3-glucan via an alkali-labile 
linkage (Figure 2). Proteins lacking a covalent attachment to the polysaccharide 
matrix may be heterogeneously distributed on the surface or secreted into the 
external milieu. These proteins may either be involved in cell wall organization, e.g., 
Bgl2p, have substrates within the cell wall, or released to the external milieu where 
they help taking up nutrients or mediating immunological interactions with host cells.  
Figure 2 Structure of 
the C. albicans cell 
wall. Picture was 
modified from Gow et 
al., 2012, Nat. Rev. 
Microbiol. 
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2.5 Glycosylation of extracellular proteins 
Cell wall and secreted proteins of C. albicans are highly modified by the 
addition of carbohydrate structures, which consist of α- and ß-linked mannose units 
(Hall et al. 2013). The mechanism of mannosylation in C. albicans has been 
extensively summarized elsewhere (Hall et al. 2013). In brief, mannose 
monosaccharides polymerize into mannan and form distinguished structures: linear 
O-linked mannan, highly branched N-linked mannan and phospholipomannan. 
Protein mannosylation is initiated during protein synthesis in the endoplasmic 
reticulum (ER) and continues in the Golgi apparatus. Initially, mannose and glucose 
residues are added to acceptor proteins from dolichol phosphate (DP)-linked sugars, 
which are synthesized by dolichol phosphate mannose synthase (DPMS) and 
dolichol phosphate glucose synthase (DPGS), respectively. The core structure of N-
mannan is a dolichol pyrophosphate-anchored oligosaccharide comprised of three 
glucose, nine mannose and two N-acetylglucosamine residues (Glc3Man9GlcNAc2). It 
is transferred to nascent polypeptides in the ER by the oligosaccharyl transfer 
complex (OST) and processed by three glucosidases (Cwh41p, Rot2p and Mns1p), 
resulting in formation of the mature core (Man8GlcNAc2). The N-mannan core is 
structurally similar in all eukaryotes, but the outer N-mannan chain is fungal specific. 
In C. albicans mannosyltransferase Och1p catalyzed the attachment of mannan to 
the N-mannan core through an α-1,6 backbone to form branched outer chain 
mannan. 
The C. albicans cell wall consists of 80-90% carbohydrates, which are 
predominantly associated with proteins on the outer layer. It is well known, that the 
cell wall carbohydrate mannan, ß-glucan and chitin are the major PAMPs presented 
to innate immune cells during infection. For example, TLR2, TLR4, dectin-2, Mincle, 
DC-SIGN and galectin-3 have major roles in the recognition of fungal mannans 
(Fradin et al. 2000; Tada et al. 2002; Porcaro et al. 2003; Taylor et al. 2004; 
Rouabhia et al. 2005; McGreal et al. 2006). Dectin-1 and complement receptor 3 are 
the major PRRs to detect ß-glucans (Thornton et al. 1996; Brown et al. 2001). 
Studies on a series of glycosylation mutants with altered mannan surface structures 
have shown that recognition of C. albicans is predominantly driven by mannan 
through TLR4 and mannose receptor (MR) in monocytes, while macrophage 
recognition is predominantly mediated by ß-glucan through dectin-1.  
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In addition, mannan and ß-glucan are also dominant antigens detected in 
systemic candidiasis patients. For this reason they are used as diagnostic biomarkers 
for Candida infections (Ostrosky-Zeichner 2012; Held et al. 2013).  
 
3 The adaptive immune response 
During host-fungal pathogen interaction, the innate immunity as the first 
defense line eliminates the majority of fungal pathogens within a short period of time. 
However, the adaptive immune response acts more specific and generates memory 
immunity for a long-term protection. 
3.1 Structure of antibodies  
One major function of the adaptive immunity upon fungal infection is 
generation of antibodies against fungal antigens. Antibodies are soluble proteins 
circulating freely and contributing to the immunity against foreign invaders, such as 
neutralization of toxins and microorganisms, recruitment of other components of the 
immune system for cellular cytotoxicity, immunomodulation and the generation of 
protective antifungal memory immunity (Janeway et al. 2005). 
  Antibody molecules are roughly Y-shaped molecules. They are generated by 
activated mature B cells in the secondary lymphoid organs (SLOs), such as the 
spleen and lymph nodes. In mammals, antibodies are divided into five isotypes, IgA, 
IgD, IgE, IgG and IgM. They basically consist of two large identical heavy chains and 
two small identical light chains. They are linked to each other by disulfide bonds. Both 
heavy and light chains are composed of constant and variable regions. The amino-
terminals of both variable domains provide two identical specific antigen binding 
sites, whereas the constant domains can interact with effector molecules and cells. 
Each B cell only produces antibodies containing a unique variable chain. The 
variable region of each antibody heavy chain is encoded by the gene segments 
variable (V), diversity (D) and joining (J). The light chain contains only V and J 
segments. Antibodies have for each gene segment multiple copies. Each variable 
region is assembled by randomly selecting and combining one V, one D and one J 
gene segment. Thus different combinations of gene segments can lead to a huge 
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number of antibodies with different antigen specificities (Figure 3) (Janeway et al. 
2005). 
 
3.2 Antibody generation 
Host antibody response is common during host-fungal pathogen interaction. It 
occurs not only during active infections caused by pathogenic fungi, but also in 
response to normal exposure to environmental fungi and as a result of 
commensalism.  
Upon infection, specialized antigen-presenting cells are activated, once they 
engulf a pathogen, which gets degraded intracellularly. Dendritic cells and B-cells 
(and to a lesser extent macrophages) are termed professional antigen-presenting 
cells (APC), which are capable of presenting antigens via major histocompatibility 
complex (MHC) molecules. Exogenous antigens are usually presented by APCs via 
MHC class II molecules, which activate CD4+ T helper cells. While endogenous 
antigens are typically displayed on the MHC class I molecules, which are expressed 
by all host cells except non-nucleated cells, and activate CD8+ cytotoxic T-cells 
(Janeway et al. 2005). 
Naive T-cells are activated when their surface T-cell receptor (TCR) interacts 
with a peptide-bound MHC molecule. The activated T-cells differentiate into mature 
T-cells and secrete cytokines to attract more macrophages, neutrophils and other 
lymphocytes to infected cells. Like T cells, each B cell expresses a unique B cell 
receptor (BCR), which recognizes and binds to only one particular antigen. Once a B 
cell encounters its specific antigen in the lymph node, it engulfs the antigen and 
digests it. Then it displays antigen fragments bound to its unique MHC molecules. 
Figure 3 Schematic representation of the 
structure of an antibody molecule (adapted from 
Immunobiology, 6/e, Janeway, by Garland 
Science publishing) 
  Introduction 
10 
 
This antigen can either be free-floating like secreted proteins or presented by APCs, 
such as dendric cells and macrophages. Also the antigens could be proteins, 
glycoproteins, polysaccharides, whole virus particles and whole bacterial cells. When 
a mature matching helper T-cell recognizes this antigen and interacts with it, further 
differentiation of B cell into an effector cell, known as a plasma cell, is triggered. 
Plasma cells can multiply and secrete antibodies. These antibodies bind to antigens, 
making them easier targets for phagocytes and trigger the complement cascade 
(Figure 4). About 10% of plasma cells develop into long-lived antigen-specific 
memory B cells, which could be called upon to respond quickly once the same 
pathogen re-infects the host (Janeway et al. 2005). 
   
Figure 4 The humoral immune response is mediated by antibody molecules that are 
secreted by plasma cells (adapted from Immunobiology, 6/e, Janeway, by Garland 
Science publishing) 
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3.3 The serological response in candidemia patients and systemically infected mice 
with C. albicans 
           The serological response in candidemia patients reflects the formed 
antibodies in patient serum in response to a systemic C. albicans infection. The 
serological survey of molecular imprints of pathogens is typically applied to the 
diagnosis of an infection. In the last decades, technologies in the fields of proteomics 
and antibody engineering have progressed rapidly. 2D-gel based immunoproteomic 
approaches and microarray techniques largely facilitate identification of Candida 
antigenic proteins in serum samples of candidemia patients and infected mice 
(Pitarch et al. 2004; Pitarch et al. 2006; Pitarch et al. 2009; Pitarch et al. 2009; 
Mochon et al. 2010; Pitarch et al. 2011; Pitarch et al. 2014). 
           As C. albicans is a commensal on the human gastrointestinal mucosal 
surface, there is a basal level of natural antibodies circulating in healthy individuals. 
Until now, the identified immunodominant protein antigens of C. albicans are mainly 
cell wall components and glycolytic enzymes, including Eno1p, mannans and Mp65p. 
A 5-IgG antibody-reactivity signature (Anti-Met6p IgG, anti-Ssb1p IgG, anti-
Gap1p/Tdh3p IgG, anti-Hsp90p IgG and anti-Pgk1p IgG antibodies) was suggested 
as a prognostic predictor for invasive candidiasis (Pitarch et al. 2011). The ß-1,3- 
glucosyltransferase Bgl2p was demonstrated to represent a putative vaccine 
candidate (Gil-Bona et al. 2015). Besides protein antigens, cell wall carbohydrates 
are also found to be highly immunoreative, such as mannan. Anti-mannan antibodies 
are prevalent in human sera, including patients, but also the general population 
(Lopez-Ribot et al. 2004). Anti-mannan antibodies can mediate a protective response 
in mice with invasive candidiasis (Han et al. 2000). Combined detection of the 
antigen mannan and anti-mannan antibodies has shown diagnostic value for Candida 
infection (Sendid et al. 2002). 
 
4 The aim of the work 
In this work, we aimed at characterizing the extracellular proteins (peptides) 
present in the culture supernatant of C. albicans yeast and hyphal cells. In order to 
characterize the constituents and changes of the secretomes during yeast-to-hypha 
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transition, we analysed C. albicans yeast and hyphal secretomes by a 2D-GE as well 
as an LC-MS/MS- based proteomic approach. Besides, we also investigated the 
peptides present in the supernatant of Candida cultures. For this purpose, solid 
phase extraction was applied for the enrichment of peptides from culture supernants.  
Further, extracellular proteins (peptides) of C. albicans are exposed to immune 
cells of the host and present a direct antigen pool for APCs in the human humoral 
immunity. Still little is known about the interplay of C. albicans secreted proteins and 
the host humoral immune response. Until now, there are no effective and specific 
molecular diagnostic biomarkers for the detection of systemic candidiasis.  Thus, the 
present work aimed to investigate the serological response profile of candidemia 
patients to secreted proteins of C. albicans. A further aim was to find a core set of 
anti-C. albicans protein antibodies which could be used as biomarkers for the 
diagnosis of C. albicans infection. 2D-immunoblotting of extracellular proteins 
combined with mass spectrometry for protein identification was applied to achieve 
this goal.  
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Materials and methods 
1 Strains and materials 
1.1 Strains 
The strains used in this work are listed in Table 1. 
Table 1 Fungal strains 
Strain name Genotype Reference 
Candida albicans 
SC5314 
 
Wild type, clinical isolate 
 
(Gillum et al. 1984) 
Pichia pastoris 
pCA2 
 
 
pCA6 
 
GS115 + pKJ113 with C. albicans SAP2 
integration 
 
GS115 + pKJ113 with C. albicans SAP6 
integration 
 
(Borg-von Zepelin et 
al. 1998) 
(Schild et al. 2011) 
 
1.2 Media and buffers 
The composition of media and buffers used in this study is described in 
Table 2. For growth of microorganisms on solid media, 2% (w/v) agar was added. 
Table 2 Media and Buffers 
Medium Components 
Candida albicans media 
YPD rich medium 
 
 
 
YNBS medium pH4.0 
 
 
 
 
 
YNBS medium pH7.4 
 
 
 
 
 
Pichia pastoris media 
BMG medium 
 
 
 
1% (w/v) yeast extract 
1% (w/v) Bacto peptone (BD Biosciences) 
2% (w/v) D-glucose 
 
0.17% (w/v) yeast nitrogen base (YNB, without amino acids and 
ammonium sulfate, BD Biosciences) 
5 g/L ammonium sulfate 
2% (w/v) sucrose 
100 mM sodium citrate buffer, pH 4.0 
 
0.17% (w/v) yeast nitrogen base (YNB, without amino acids and 
ammonium sulfate, BD Biosciences) 
5 g/L ammonium sulfate 
2% (w/v) sucrose 
5 mM GluNAc 
75 mM MOPS, pH 7.4 
 
100 mM potassium phosphate buffer, pH 6.0 
1.34% (w/v) YNB with ammonium sulfate (BD Biosciences) 
4 ×10-5 % (w/v) biotin 
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BMM medium 
 
 
Escherichia coli media 
Buffers 
PBS pH 7.4 
 
 
 
 
Sodium citrate buffer  
0.1 M pH 4.0 
 
MOPS buffer 
75 mM pH 7.4 
1% (v/v) glycerol 
As BMG, but 0.5% (v/v) methanol instead of 1% glycerol 
 
LB medium 1% (w/v) Bacto tryptone (BD Biosciences) 
0.5% (w/v) yeast extract 
1% (w/v) NaCl 
 
 
140 mM NaCl 
2.7 mM KCl 
10 mM Na2HPO4 
1.8 mM KH2PO4 
 
 
0.1 M citric acid : 0.1 M sodium citrate (59:41) 
 
 
Adjust pH to 7.4 with NaOH 
 
1.3 Serum samples 
1.3.1 Mouse serum samples 
In this work mouse serum samples were used for the investigation of the 
serological response of mice against secreted proteins of C. albicans yeast cells. The 
mouse serum samples used in this work are described in table 3. Here the classical 
systemic infection model was applied in almost all the mice experiments except for 
Ca3-10. In brief, C. albicans wild type, mutant or complemented strains were 
intravenously injected into the tail vein of immunocompetent female BALB/c mice. For 
mice survival experiments, an infectious dose of 1×104 /g was applied and mice were 
sacrificed if moribund, whereas a higher infectious dose of 2.5×104 /g was used for 
fungal burden experiment and mice were sacrificed at predefined time points. In 
microevolution experiments two mice per passage were challenged intravenously 
with 5×103 C. albicans cells per gram body weight. After 14 days of infection 
C. albicans cells were removed from the infected kidney and passed to the next 
passage of mice. The details of above described mice experiments are described in 
Lüttich et al. (Luttich et al. 2013) and Hennicke et al. (Hennicke et al. 2013). Besides, 
in the Ca3-10 mice experiment, the intraperitoneal model was used. Briefly, 1 × 108 
C. albicans cells / 500 µl were injected intraperitoneally, mice were sacrificed after 12 
and 24 h. More details about this infection model are described in the reference 
(Thewes et al. 2007). In all animal experiments, the German animal protection law 
was followed and experiments were approved by the responsible Federal State 
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authority (Thüringer Landesamt für Lebensmittelsicherheit und Verbraucherschutz) 
and ethics committee. 
Table 3 Mouse serum samples 
Mouse experiments Genotype 
(C.albicans SC5314) 
Cage/animal Lifetime 
(day) 
Ca1-10 (10/02-24/02/2010) 
Microevolution, systemic infection, 
Infectious dose: 5×103 /g 
wt S7 14  
wt S8 14 
wt S11 14 
Ca1-11 (27/01-17/02/2011) 
Fungal burden, systemic infection, Infectious 
dose: 2.5×104 /g 
wt 2/8 2 
ssu1∆ 3/4 5 
SSU compl. 6/7 5 
Ca3-11 (01/04-21/04/2011) 
Survival experiment, systemic infection, 
Infectious dose: 1×104 /g 
wt, CAI4+pClp10 1/5 7 
efg∆cph∆ (Evo 0) 3/2 20 
efg∆cph∆ (Evo 0) 3/4 20 
efg∆cph∆ (Evo 0) 4/7 20 
Evo X 5/1 8 
Evo X 6/8 7 
Evo X 6/9 14 
Ca4-11 (03/04-07/04/2011) 
Fungal burden, systemic infection, 2.5×104 /g 
wt, CAI4+pClp10 1/1 2 
wt, CAI4+pClp10 2/6 4 
Ca5-11(29/03-19/04/2011) 
Survival experiment, systemic infection, 
Infectious dose: 1×104 /g 
wt 1/3 8 
wt 1/5 8 
ssu1∆ 4/6 9 
SSU compl. 6/6 7 
cdg∆ 7/5 20 
cdg∆ 8/8 11 
CDG compl. 9/5 14 
CDG compl. 10/8 12 
Ca3-10 (12/07/2010) 
intraperitoneal model 
wt B 20 min 
PBS control    
 
1.3.2 Human serum samples 
Serum samples, derived from six patients with severe sepsis due to 
candidemia and five patients with sterile systemic inflammatory response syndrome 
(SIRS) due to acute pancreatitis were used. These samples originated from the large 
collection of biomaterial of patients with sepsis of the Hellenic Sepsis Study Group 
(Registry reference www.sepsis.gr). Enrolled patients were hospitalized at the 4th 
Department of Internal Medicine and at the 2nd Department of Critical Care Medicine 
of ATTIKON University Hospital, at the Intensive Care Units of Tzaneion Piraeus 
Hospital and of Laikon Athens General Hospital and at the 2nd Department of Internal 
Medicine of Sismanogleion Athens General Hospital. The registered study protocols 
  Materials and methods 
16 
 
were approved by the Ethics Committee of the hospitals and written informed 
consents were provided by the first degree relatives because patients were not able 
to consent. Blood was sampled within the first 24 hours from onset of signs of SIRS. 
Patients with neutropenia, primary immunodeficiency, HIV infection and chronic 
intake of corticosteroids were excluded from the study. Six individual serum samples 
without clinical or microbiological evidence and with a similar age to candidemia 
cases were collected from the University Hospital Jena after institutional approval by 
Local Ethics Committee Jena and evaluated as negative controls. Written informed 
consents were given by all the patients. Base-line characteristics of the study patients 
and controls are shown in Table 4. 
Table 4 Base-line characteristics of the study patients and controls 
Characteristic 
Candidemia Negative controls 
C.albicans        
(n=5) 
SIRS patients 
(n=5) 
Bacteremia 
(n=5) 
pre-OP3 patients 
(n=6) 
Demographic factors 
    Sex 
    Male 3 1 2 3 
Female 2 2 3 4 
Age (median) 64 58 71 64 
≤ϲϱ years 3 2 1 4 
˃ϲϱ years 2 1 4 3 
Positive blood culture (C. albicans) 5 / / / 
Bacterial Infection 3 / 5 / 
Underlying diseases 
        Solid tumor 1 /  n.a.4 n.a.  
    Respiratory dysfunction 3 / n.a.  n.a.  
    Gastrointestinal pathology / 4 n.a.  n.a.  
    Gallbladder stones 1 / n.a.  n.a.  
    Acute pancreatitis / 4 n.a.  n.a.  
    Heart failure 1 / n.a.  n.a.  
    COPD1 3 / n.a.  n.a.  
    Nephrolithiasis / 1 n.a.  n.a.  
Risk factors for SC2 
       Latrogenic predisposing factors 
       Broad spectrum antibiotics 5 1 n.a.  n.a.  
   Immunosuppressive therapy 1 / n.a.  n.a.  
   Central venous catheters 3 / n.a.  n.a.  
   Parenteral nutrition 3 / n.a.  n.a.  
   Underlying malignancy 1 / n.a.  n.a.  
Outcome of hospital stay 
       Death 1 / 1 n.a.  
   Discharge 4 5 4 n.a.  
1: COPD: Chronic obstructive pulmonary disease; 
2: SC: systemic candidiasis;       3: Pre-OP: before operation;          4: n.a.: not applicable 
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1.3.3 Recombinant C. albicans Sap6p expressed in Pichia pastoris  
Recombinant C. albicans Sap6p was expressed in P. pastoris (Komagataella 
pastoris) (Invitrogen) and purified by cation exchange chromatography on an SP-
sepharose column, followed by desalting through a Sephadex G25 column. The 
protein sample was resolved in 0.1 M sodium citrate buffer, pH 4.5 as described in 
previous studies (Borg-von Zepelin et al. 1998; Schild et al. 2011). 
 
2 Organism and growth conditions 
2.1 C. albicans growth conditions 
C. albicans strain SC5314 was used throughout this study (Gillum et al. 1984). 
Yeast cells were pre-cultured overnight in YPD medium on a rotary shaker with 
200 rpm and at 30 °C and then transferred to flasks containing YNBS medium (pH 4). 
Pre-cultures in YNBS (OD=1) were used to inoculate a fermenter (Sartorius Stedim 
biotech Biostat® D-DCU 10L, Göttingen, Germany) for a batch cultivation of 
C. albicans yeast or hyphal cells.  
 
2.2 Fermenter cultivation of C. albicans 
For batch cultivation of yeast cells, a fermenter containing YNBS (5 g/L 
ammonium sulfate, 1.7 g/L nitrogen base, 20 g/L sucrose and 75 mM citric acid – 
sodium citrate buffer, pH 4) was inoculated with C. albicans yeast cells at an initial 
OD600 of 0.05. Cultivation was performed in a culture volume of 6 L at 30 °C, at a 
constant pressure of 400 mbar and at a maximum stirring rate of 400 rpm for 15 
hours. For hyphal induction, 6L YNBS medium [5 g/L ammonium sulfate, 1.7 g/L 
nitrogen base, 20 g/L sucrose, 75 mM MOPS [3-(N-morpholino) propanesulfonic 
acid] (pH 7.4), supplemented with 5 mM N-acetylglucosamine (GlcNAc) was 
inoculated with a preculture of C. albicans yeast cells as described above at a 
temperature of 37 °C, a constant stirring rate of 100 rpm and a continuous pressure 
of 400 mbar for 18 hours.  
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2.3 Viability assay of C. albicans cells 
   Once C. albicans cells were harvested, the morphology of the cells was 
checked under the light microscopy to ensure the presence of one single 
morphotype, yeast or hyphae. Also the viability of the cells was monitored by 
fluorescent microscopy by means of propidium iodide staining. Propidium iodide with 
1 mg/ml was added to 3 ml culture to give a final concentration of 10 µg/ ml. After 15 
minutes of incubation in the darkness, the samples were checked by fluorescence 
microscopy. The detection of signals was performed according to the standard 
protocol of red fluorescent protein (RFP). 
 
3 Protein biochemical methods 
3.1 Isolation of secreted proteins from growth media 
For the isolation of extracellular proteins, C. albicans cells were spun down at 
12,000 × g and the supernatant was filtered with a 0.2 µm filter (PES, Millipore). 
Secreted proteins were precipitated overnight at 4 °C by the addition of 10 % (w/v) 
trichloroacetic acid (TCA) and 3 mg/ml DTT. After centrifugation for 1 hour at 30,000 
× g at 4 °C the supernatant was discarded and protein pellets were washed two times 
with 90% (v/v) ice-cold acetone and centrifuged at 13,000 × g for 1 hour at 4°C. The 
pellets were air-dried for 10 min and resuspended in 2D lysis buffer [7 M urea, 2 M 
thiourea, 4% (w/v) CHAPS, 0.8% (v/v) pharmalyte (GE healthcare Life Sciences)] for 
2D gel electrophoresis as described in Wartenberg et al. (2011). After solubilization 
of the protein pellet，samples were centrifuged at 20,000 × g for 15 min at room 
temperature and the supernatant was transferred to a new microcentrifuge tube. The 
protein concentration was measured using the Bio-Rad Protein Assay-Dye Reagent 
Concentrate (Bio-Rad, Munich).  
 
3.2 Gel-based Proteomics 
3.2.1 Two-dimensional gel electrophoresis (2D-GE) 
For yeast and hyphal secretome analyses, 2D gel electrophoresis was carried 
out as described in Wartenberg et al. (2011) with slight modifications. The amount of 
350 µg proteins per sample was loaded via sample cups on 24 cm IPG strips 
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(Immobiline DryStrip, GE Healthcare, Germany) that covered a pH range of either 4-7 
or 7-11NL (non-linear). Isoelectric focusing was performed using an IPGphor II 
device (GE Healthcare, Germany) with the following program: 4 h for gradient 300V, 
4 h for gradient 600V, 4 h for gradient 1000V, 4 h for gradient 8000V and 48,000Vhs 
at 8000V. Then, IPG strips were equilibrated with SDS equilibration buffer containing 
1% (w/v) DTT for 15 min with gentle agitation, followed by equilibration with SDS 
equilibration buffer containing 2.5% (w/v) iodoacetamide. The second dimension was 
performed using self-casted 12.5% (w/v) polyacrylamide Tris/HCl gels and an Ettan 
Dalt Six electrophoresis unit (GE Healthcare, Germany). Gel electrophoresis was 
performed at 15 W/gel at 20 °C for 4 hours. Gels were stained with colloidal 
Coomassie G250 (Dyballa et al. 2009). 
3.2.2 Protein identification using MALDI-TOF/TOF analysis 
Excised protein spots were in-gel digested with trypsin as described in 
Shevchenko et al. (1996). The resulting peptides were extracted from gel pieces with 
extraction buffer (50% ACN in 0.05% TFA) and resuspended in an ultrasonic bath. 
For MALDI-TOF/TOF analysis samples were reconstructed in 10 mg/ml HCCA 
solved in solution [30% / 70% (v/v) ACN / 0.1% TFA]. The samples were measured 
on an ultrafleXtreme MALDI-TOF/TOF device (Bruker Daltonics, Germany). MS 
spectra (m/z 700-3500 Da) were acquired and the 10 most intense precursor ions 
were selected for MS/MS fragmentation. FlexControl 3.3 software was used for data 
collection and flexAnalysis 3.3 for spectra analysis and peak list generation. The 
generated MS and MS/MS spectra were analyzed by searching the Candida Genome 
Database (http://www.candidagenome.org/) using MASCOT 2.3 server (Matrix 
Science, UK). Search parameters were the following: oxidized methionine as variable 
modification, carbamidomethyl cysteine as fixed modification, one miscleavage and a 
pepide mass tolerance of 100 ppm and a fragment mass tolerance of 0.6 Da. Results 
were regarded as significant with an allowed likelihood for a random hit of p ≤ 0.05, 
according to the Mascot score. Three to four biological replicates of secretome 
samples from each morphological form were analyzed. 
3.2.3 Protein identification using LC-MS/MS analysis 
Samples not identified by MALDI-TOF-TOF, were further analyzed by LC-
MS/MS. They were solved in 10 µL aqueous 1% (v/v) formic acid. Depending on the 
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protein amount, 5-10 µL of the sample were injected into LC-MS/MS system 
consisting of a nanoAcquity UPLC system (Waters, Manchester, UK) on-line coupled 
to a Synapt HDMS tandem mass spectrometer (Waters, Manchester, UK). LC-
MS/MS data were collected using data-dependent acquisition (DDA). Each 
acquisition cycle consisted of a survey scan covering the range of m/z 400-1500 amu 
followed by MS/MS fragmentation of the four most intense precursor ions collected 
over a 1 sec interval in the range of 50-1700 m/z. Dynamic exclusion was applied to 
minimize multiple fragmentations for the same precursor ions.  
          DDA raw files were collected using MassLynx v4.1 software and processed 
using ProteinLynx Global Server Browser (PLGS) v.2.5 software (Waters, 
Manchester, UK) under baseline subtraction, smoothing, deisotoping, and lockmass-
correction. Pkl files of MS/MS spectra were generated and searched against NCBInr 
database (updated December, 05, 2012, installed on a local server) using MASCOT 
version 2.4. Mass tolerances for precursor and fragment ions were 15 ppm and 0.03 
Da, respectively. Other search parameters were: instrument profile, ESI-Trap; fixed 
modification, carbamidomethyl (cysteine); variable modification, oxidation 
(methionine); up to one missed cleavage was allowed.  
 
3.3 Gel-free LC-MS/MS analysis 
3.3.1 Protein sample preparation 
The secretome of C. albicans was also characterized by LC-MS/MS analysis. 
Protein pellets obtained after TCA precipitation were resolubilized in 50 µl 50 mM 
NH4HCO3 in 50%/50% (v/v) trifluoroethanol /water and ultrasonicated for 15 min and 
subsequently denaturated at 90 °C for 15 min. Cysteine residues were reduced by 
addition of 5 µL 200 mM DTT and incubation for 20 min at 50 °C. Subsequently, 
reduced cysteine residues were carbamidomethylated for 30 min at room 
temperature in the dark by applying 5 µL 1 M iodoacetamide. Afterwards, samples 
were diluted approximately 1:10 with 445 µl 50 mM NH4HCO3 (pH 8) to gain a final 
TFE concentration of <5 %. Proteins were digested for 18 h at 37 °C with Trypsin-
LysC mix (Promega, USA) at a ratio of 1:25 trypsin to protein. The reaction was 
stopped by acidification with formic acid. Finally, samples were dried in a SpeedVac 
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and resolubilized in 20 µL 0.05% TFA in 98%/2% (v/v) water/ACN for LC-MS/MS 
measurement. 
3.3.2 LC-MS/MS analysis 
          LC-MS/MS analysis was carried out on an Ultimate 3000 nano RSLC system 
coupled to a QExactive Plus mass spectrometer (both Thermo Fisher Scientific). 
Peptides were enriched and desalted online based on a pre-concentration set-up 
using a nano-trap column (Acclaim Pep Map 100, 2 cm x 75 µm, 3 µm) at a flow rate 
of 5 µL/ min. After 4 min, a valve switch was performed to elute the pre-concentrated 
peptides onto the analytical column. For separation of peptides, an Acclaim Pep Map 
RSLC column (15 cm × 75 µm, 2 µm) was used as stationary phase (Thermo Fisher 
Scientific). The binary mobile phase consisting of A) 0.1% (v/v) formic acid in H2O 
and B) 0.1% (v/v) formic acid in 90/10 ACN/H2O was applied for 135 min gradient 
elution: 0-5 min at 4% B, 85 min at 30% B, 95 min at 45% B, 100-109 min at 90% B, 
110-135 min at 4% B. LC performance was routinely checked by cytochrome C 
standard digest and blind injections prior and after analysis and by monitoring UV 
absorption at λ = 214 nm during analysis. The Nano-spray Flex Ion Source (Thermo 
Fisher Scientific) provided with a stainless steel emitter was used to generate 
positively charged ions at 2.0 kV spray voltage. The capillary temperature was set to 
220 °C and the S-lens RV level to 50. The mass spectrometer was calibrated 
externally prior to the analysis with positive CalMix solution and internally based on 
the lock mass of m/z 445.12003 amu for [C2H6SiO]6 (polydimethylsiloxane). The 
hybrid quadrupole/orbitrap mass analyzer was operated in Full MS / dd MS2 (TopN) 
mode. Precursor ions were measured in full scan mode within a mass range of m/z 
350-1700 at a resolution of 35k FWHM using a maximum injection time of 120 ms 
and an AGC (automatic gain control) target of 1e6. For data-dependent acquisition, 
up to 10 most abundant precursor ions per scan cycle with an assigned charge state 
of z = 2-4 were selected in the quadrupole for further fragmentation using an isolation 
width of m/z 2.0. Fragment ions were generated in the HCD cell at a normalized 
collision-energy of 30 V using nitrogen gas. Dynamic exclusion of precursor ions was 
set to 30 s. The LC-MS/MS instrument was operated by means of the Thermo/Dionex 
Chromeleon Xpress v6.80 SR13 build 3818 software and the Thermo QExactive Plus 
Tune /Xcalibur v3.0.63 2.3 build 1765 graphical interface software. 
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3.3.3 Bioinformatic analysis 
The CGD (www.candidagenome.org) database was used for database 
searches. Search algorithms of Mascot v2.4.1 (Matrix Science, UK), Sequest HT and 
MS Amanda were used to identify proteins. Two missed cleavages were allowed for 
trypsin digestion. Oxidation of Met and carbamidomethylation of Cys were considered 
as dynamic and static modifications, respectively. Percolator node and a reverse 
decoy database was used for (q-value) validation of the peptide spectral matches 
(PSMs) using a maximum Delta CN of 0.05 and a strict target false discovery (FDR) 
rate of < 1%. At least two peptides per protein identified in two replicates were 
required for positive protein hits. The LC-MS/MS proteomics data were deposited to 
the ProteomeXchange Consortium (Vizcaino et al. 2014) via the PRIDE partner 
repository with the dataset identifier PXD003201 and 10.6019/PXD003201. Identified 
proteins were classified by using the GO Slim Term 
(http://www.candidagenome.org/cgi-bin/GO/goTermMapper) according to their 
biological processes. Signal peptide prediction was done by using SignalP4.1 Server 
(http://www.cbs.dtu.dk/services/SignalP/). To predict the GPI modification sites the 
program Big PI Predictor was applied (http://mendel.imp.ac.at/gpi/gpi_server.html). 
 
3.4 Quantitative analysis of C. albicans secretome via TMT labeling 
           For quantitative analysis of C. albicans secretome, three biological replicates 
of yeast secretome samples and hyphal samples were respectively labeled with 
TMT6plex tags. For each experiment two technical replicates were done and for each 
replicate three measurements were performed. 
3.4.1 Protein sample preparation 
Protein pellets obtained after TCA precipitation and 3 washing steps with 90% 
acetone, were resolubilized in 150 µl denature buffer [45 mM TEAB (triethyl 
ammonium bicarbonate) + 0.1% SDS + cOmplete protease inhibitor 
cocktail/PhosSTOP 1 tablet for 10 ml] in 50%/50% (v/v) trifluoroethanol /water and 
ultrasonicated for 15 min and subsequently denaturated at 90 °C for 15 min. Cysteine 
residues were reduced by addition of 5 µL reduction buffer [200 Mm TCEP (tris-2-
carboxyethylphosphine) in 200 mM TEAB] and incubation for 60 min at 55 °C. 
Subsequently, reduced cysteine residues were carbamidomethylated for 30 min at 
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room temperature in the dark by applying 5 µL alkylation buffer (375 mM 
Iodacetamide in 100 mM TEAB). Then proteins were precipitated from the solution 
using methanol/chloroform method. Protein pellets were dried and resolubilized in 
100 µl 100 mM TEAB solution. Proteins were digested for 18 h at 37 °C with Trypsin-
LysC mix (Promega, USA) at a ratio of 1:25 trypsin to protein. After that samples 
were ready and prepared for TMT labeling. 
Each TMT6plex labeling vial (0.8 mg) was resolublized with 41µl ACN. Each 
protein sample was transferred to one TMT6plex-vial, as described in the supplement 
table 5. After 1 hour of incubation at room temperature the reactions were stopped by 
the addition of 5% hydroxylamine in 180 mM TEAB for 15 min incubation time. 
Subsequently, all the 6 labeled samples were mixed together in a new 
microcentrifuge tube. Finally, samples were dried in a SpeedVac and resolubilized in 
20 µL 0.05% TFA in 98/2 (v/v) water/ACN for LC-MS/MS measurement 
3.4.2 LC-MS/MS analysis and bioinformatic analysis 
        The samples were analyzed by LC-MS/MS as described in chapter 3.3.2 and 
3.3.3. 
 
3.5 2-DE and immunoblot analysis 
           For immunoblots, 80µg protein samples were loaded on 11 cm IPG strips (GE 
Healthcare) covering a pH range of 3-11 NL (non-linear). The program for isoelectric 
focusing was as following: 3h for gradient 300V, 4h for gradient 600V, 4h for gradient 
1000V, 4h for gradient 8000V and 24,000Vhs at 8000V. After equilibration of IPG 
strips as described, the gel electrophoresis was performed by using any kD™ 
Criterion™ TGX Stain-Free™ gels (Bio-Rad, Germany). Gels were scanned by the 
Gel Doc EZ system (Bio-Rad, Germany). Proteins were transferred to the PVDF 
membrane with low fluorescent background (Immobilon® FL-Membrane, Merck 
Millipore, US) at 0.6 A for two hours by tank blotting (Trans-Blot® Cell, Bio-Rad). Blots 
were blocked with 1% (w/v) casein (Western blocking reagent, Roche, Switzerland) in 
TBST washing buffer [TBS containing 0.1% (v/v) Tween 20] for 1 hour, followed by 
incubation with human serum at a 1:1000 dilution for 1 hour. After three washing 
steps, blots were scanned by the Bio-Rad Gel Doc EZ system. The upper left corner 
of the blotting membrane was cut off and both parts of the blot were separately 
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incubated for 1 hour with an anti-IgG secondary antibody (Goat anti-Human 
Immunoglobulin G antibody, HRP conjugate, Merck Millipore, US) at a dilution of 
1:100,000 and 1:20,000, respectively. After three washing steps, immunoblots were 
covered with the Immuno-Blue fluorescent substrate (NH DyeAGNOSTICS, 
Germany). Fluorescent signals were visualized by using a VersaDoc MP 4000 
imaging system (Bio-Rad, Germany). Gel images, protein imprint on the membrane 
blot and signal images of immunoblots were compared by means of the gel imaging 
software Delta 2D 4.5 (Decodon, Germany).  
 
3.6 Glycoprotein staining 
For detection of glycoproteins in PA gels the Glycoprotein staining kit (G-
Biosciences, USA) was used. 
 
3.7 Deglycosylation of recombinant Sap6p protein and secretome samples 
          The Protein Deglycosylation Mix (New England BioLabs, Ipswich, MA) was 
applied for deglycosylation of recombinant proteins and secretome samples. 
 
3.8 Peptides enrichment via SPE 
For SPE experiment, the preculture of C. albicans was carried out as 
described in chapter 2.1. The induction of hypha formation was performed in shaking 
flasks for 18 hours at 37 °C and shaking at 200 rpm. 
The medium supernatant was sterile filtered through a PES membrane with a 
pore size of 0.2 µm. To the filtered supernatant, an EDTA-free cOmplete protease 
inhibitor tablet (1 tablet per 100ml, Roche), EDTA, pH 8 (0.4 mM) and benzamidine 
(1 mM) were added. Peptides were enriched based on a two-step solid phase 
extraction (SPE) enrichment protocol using first a C4 resin. The flow-through was 
subsequently enriched on a C18 resin. For every enrichment process, each column 
was firstly wetted with 5 ml acetonitrile (ACN), followed by 5 ml 0.05% trifluoroacetic 
acid (TFA) equilibration, sample loading, washing with 5 ml 2% ACN and 0.05%TFA 
and elution with 80% ACN and 0.05% TFA. The eluate after C4 and C18 enrichment 
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steps was collected in microcentrifuge tubes and dried in speed-vac. Before LC-
MS/MS measurement the sample was filtered with 10kDa MWCO spin filters, dried in 
a vacuum centrifuge and resolubilized in loading solution [0.2% formic acid in 71:27:2 
ACN/H2O/DMSO (v/v/v)]. 
 
3.9 ELISA assay for the determination of sera IgG titers directed against C. albicans 
secreted proteins 
           0.1 µg C. albicans hyphal proteins were coated on the bottom of wells of a 96- 
microtiter plate with carbonate-bicarbonate buffer, overnight at 4 °C with mild 
shaking. The wells were washed 3 times with TBST [0.1% (v/v) Tween 20] buffer and 
subsequently blocked with 1% (w/v) casein in TBS buffer for 2 hours. Then, washing 
steps were repeated. Patients´ sera were diluted 1:1000 in blocking solution and 
incubated for 30 min at room temperature. The patients´ sera that were used in this 
ELISA assay are listed and described in the supplementary table S-4. After repeating 
the washing step goat anti-human IgG secondary antibodies, which were diluted 
1:50,000 in blocking solution, were added and incubated for 30 min at room 
temperature. After a final washing step, 50 µl /well TMB were added as chromogenic 
substrate and incubated for 15 minutes. The color reaction was stopped by the 
addition of 2 M H2SO4 (50µl/well). Subsequently the microtiter plate was analyzed by 
using a spectrophotometer at a wavelength of 450nm. 
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Results 
1 Cultivation of C. albicans in a fermenter 
C. albicans yeast cells usually do not secrete a large number of proteins into 
the medium (Sorgo et al. 2010). To obtain the required amount of protein for 2D gel-
based secretome analysis we established a batch cultivation of C. albicans yeast and 
hyphal cells, respectively, to overcome the limitations of shaking flask cultures. 
C. albicans yeast cells were cultivated in the YNB medium (pH4) and hypha 
formation were induced by the addition of GlcNAc as inducer and increasing the 
temperature and pH.  During the whole cultivation, the pH and temperature were 
monitored and kept constant. The morphology and viability of C. albicans cells were 
checked under the microscope after cell harvest. Only one morphotype (yeast or 
hypha) was detectable in the corresponding cultures.  
 
1.1 Growth curve of C. albicans yeast cells during fermentation 
In order to investigate the growth behavior of C. albicans yeast cells in a 10 L 
fermenter, a preliminary fermentation experiment was carried out for 3 days. Figure 
5A shows that C. albicans yeast cells reached the end of the exponential growth 
phase after 20 hours cultivation based on the development of the cell density. Figure 
5B shows that the sucrose in the growth medium was completely depleted after 3-
day cultivation. Figure 5C illustrates that nitrogen (NH4+) and phosphate (PO43-) were 
still present in sufficient amounts for effective growth after 3 days of fermentation. 
The plotting of the CO2 concentration released by C. albicans yeast cells reached its 
maximum after 15 hours of fermentation (in the supplement Figure S1). The CO2 
evolution rate usually correlates well with the yeast growth kinetics. For this reason, 
we set the fermentation time of C. albicans yeast cells to 15 hours, which allowed us 
to harvest viable, actively growing C. albicans cells. 
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A.                                                              B. 
                  
C. 
 
Figure 5. Growth curve of C. albicans yeast cells and consumption of sucrose, 
nitrogen and phosphate. A) Development of cell density within 20 hours of fermenter 
cultivation; B) Consumption of sucrose; C) Consumption of nitrogen (NH4+) and 
phosphate (PO43-) in the medium during a three-day cultivation 
 
1.2 Growth curve of C. albicans hyphal cells during the fermentation 
We observed the dynamics of the biomass development of C. albicans hyphal 
cells during the cultivation for 4 days in a 10 L fermenter. Figure 6 shows that hyphal 
cells were growing in a linear mode during the 4-day cultivation period. Within the 
linear phase a short interval of reduced growth appeared. Due to quorum sensing, 
the induced hyphal cells of C. albicans may switch back to yeast cells when a certain 
cell density is reached. Indeed, the microscopic monitoring of C. albicans cells 
revealed that hyphal cells start to switch back to the yeast form after 18 hours of 
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fermentation. For this reason we set the fermentation time for Candida hyphal cells to 
18 hours. 
 
 
1.3 Viability test of C. albicans cells 
After each cell harvest, we checked the morphology and viability of cells by 
light and fluorescent microscopy. Propidium iodide was applied for viability staining. 
Figure 7 shows that almost all yeast cells were vital, while hyphal cells clumped 
together and a small amount of hyphal cells (less than 10% of the total number of 
cells) showed a positive propidium iodide fluorescence signal.  
 
Figure 7 Cell viability assays of C. albicans yeast and hyphal cells after fermentation. 
Dead cells were detected by propidium iodide fluorescence staining. 
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Figure 6 Growth curve of C. albicans 
hyphal cells during batch cultivation. 
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2 Secretome analysis of C. albicans during a yeast-to-hypha transition 
To obtain a comprehensive secretome map of C. albicans, both 2D gel based- 
and LC-MS/MS based-proteomic approaches were applied for the analysis the 
secretomes of C. albicans yeast and hyphal cells. The secreted protein samples were 
prepared by precipitation of proteins from the supernatant of C. albicans culture with 
TCA. After several washing and drying steps the protein pellets were resuspended in 
either urea sample buffer for 2D-GE or trifluoroethanol buffer for LC-MS/MS 
proteomic analysis. 2D gel-based and LC-MS/MS-based secretome analysis were 
both carried out with four biological replicates of yeast and hyphal secretome 
samples, respectively. 
 
2.1 2D gel-based secretome analysis  
For a better spatial separation of protein spots, IPG strips with a pH range of 
4-7 and 7-11 were applied. Notably, no protein spots were detected in a pH range of 
7 to 11 on 2D gels of secreted yeast proteins, while on 2D gels covering a pH range 
of 4-7, some high abundant protein spots could not be separated well, which 
occupied a rather large area in the upper-left corner. These spots turned out to 
mainly consist of the mannoprotein Mp65p and other abundant cell wall proteins like 
Sun41p, Tos1p and Kar2p (Figure 8A).  
2D-gel electrophoretic separation of the hyphal secretome revealed that most 
secreted proteins have an acidic pI, but a small fraction of alkaline proteins was also 
detectable, mainly Sap5p and Sap6p (Figure 8B). Of a total of 579 excised protein 
spots, 412 were identified by MALDI-TOF/TOF representing 22 different yeast 
proteins and 141 different hyphal proteins. Spot labeling and protein identification are 
listed in the supplement Figure S-3 and Table S-1. The identified extracellular 
proteins are mainly associated with stress responses, carbohydrate metabolic 
processes and transport. 33 out of 155 identified proteins contained an N-terminal 
signal peptide for secretion based on in silico prediction and three proteins exhibited 
a predicted GPI anchor attachment signal. 
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Figure 8 2D maps of the C. albicans yeast and hyphal secretome. A) 2D secretome 
map of C. albicans yeast cells; B) 2D secretome map of C. albicans hyphal cells. The 
pH gradient is indicated and the molecular weight of the protein marker is given. 
 
2.2 Gel-free secretome analysis of C. albicans  
2.2.1 Qualitative analysis of C. albicans secretome 
For LC-MS/MS-based characterization of the C. albicans secretome, proteins 
from four biological replicates were analyzed by LC-MS/MS in three technical 
replicates. A total of 83 yeast proteins and 364 hyphal proteins were identified in at 
least three biological replicates with at least two peptides identified in more than two 
of three technical replicates (Supplement Table S-1). These proteins were mainly 
associated with regulation of biological processes, response to stress and chemicals, 
transport, translation and carbohydrate metabolic processes (Figure 9). Hyphal cells 
secreted more proteins than yeast cells, particularly proteins related to translation. 
Among them, 106 proteins contained an in silico predicted signal peptide and 21 a 
predicted GPI anchor (Supplement Table S-1). 
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Figure 9 Categorization of secreted yeast and hyphal proteins identified by LC-
MS/MS according to their potential biological process using CGD Gene Ontology slim 
mapper. 
 
2.2.2 Quantitative analysis of C. albicans secretome 
Tandem mass tag TMTsixplex labeling was applied for quantitative analysis of 
C. albicans secretome. The relative abundance of secreted proteins, which were 
shared by yeast and hyphal cells, were determined via TMT reporter ions. Therefore, 
the ratio of abundance of a certain protein allows to determine the relative changes (-
fold changes) of this secreted protein during the yeast-to-hypha transition. The 
protein amount was normalized to the biomass, in our case to the cell dry weight. 
Only 7 proteins were more than 2-fold abundant in yeast than in hyphal cells, 
whereas 155 proteins were more than 2 fold enriched in hyphal in comparison to 
yeast cells (supplement Table S-2). Proteins Ape3p, Rbt1p, Als3p, Rct1p and Abg1p 
were the most 5 “upregulated” secreted proteins during the yeast-to-hypha transition, 
whereas Ywp1p, Dag7p, Als4p, Plb4.5p and Rbe1p were the top 5 most 
“downregulated” proteins in hyphae (Table 5) 
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Table 5 The top 5 of most “up- and downregulated” proteins during yeast-to-hypha 
transition  
Average Ratio 
Hyphae/yeast 
Ratio 
Hyphae/Yeast 
 Normalized to 
biomass 
Accession Gene   Protein Description Σ# PSMs* 
2,230 5,945 orf19.3591 APE3 Putative vacuolar aminopeptidase Y 296 
2,200 5,866 orf19.1327 RBT1  Cell wall protein with similarity to Hwp1 197 
2,182 5,819 orf19.1816 ALS3  Cell wall adhesin 277 
2,109 5,623 orf19.7350 RCT1 Fluconazole-induced protein 65 
2,036 5,430 orf19.1597 ABG1  Vacuolar membrane protein 204 
0,044 0,117 orf19.3618 YWP1 Secreted yeast wall protein 89 
0,156 0,415 orf19.4688 DAG7  Secretory protein; a-specific, alpha-factor induced 114 
0,171 0,455 orf19.4555 ALS4  GPI-anchored adhesin 28 
0,172 0,459 orf19.1442 PLB4.5 Phospholipase B 414 
0,178 0,474 orf19.7218 RBE1 Pry family cell wall protein 104 
* Σ#PSMs: the total number of identified peptide spectra matched for the protein  
 
2.3 Comparison of the composition of the C. albicans yeast and hyphal secretome  
Combining the data of 2D gel- and LC-MS/MS-based proteomic methods led 
to the detection of a total of 101 extracellular yeast and 410 extracellular hyphal 
proteins (Figure 10A). 65 proteins were shared by both cell morphologies, while 36 
proteins were exclusively detected in yeast cells and 345 in hyphal cells (Figure 10A). 
The secreted yeast and hyphal proteins were categorized according to their biological 
process using CGD Gene Ontology slim mapper. In the yeast secretome, 39 cell 
wall-associated proteins (38 %), 11 proteins in response to environmental stimuli (11 
%), 9 secreted proteases, lipases and adhesins (9 %), 8 carbohydrate metabolism-
associated proteins (8 %) and 6 vesicle-mediated transport proteins (6 %) 
represented the major fraction of all secreted proteins (Figure 10B). By contrast, the 
hyphal secretome was enriched in proteins of the categories: cell wall-associated (18 
%), translation (16 %), response to stimuli (13 %), carbohydrate metabolic process (9 
%), and regulation of biological function (7 %) (Figure 10D). Altogether, 60 
extracellular yeast (59 % of all identified proteins) and 86 hyphal proteins (21 % of all 
identified proteins) were predicted as secretory proteins based on the presence of an 
N-terminal signal peptide for secretion (SignalP4.1 server prediction). Among these 
proteins, 14 and 16 contained GPI-anchor attachment signals in yeast and hyphal 
cells, respectively (Figure 10C).  
  Results 
33 
 
 
Figure 10 Comparison of the C. albicans yeast and hyphal secretome. A) Venn 
diagram for description of the numbers of identified secreted proteins in C. albicans 
yeast and hyphal cells; B) and D) Functional categorization (biological process) of the 
secreted protein in yeast (B) and hyphal cells (D); C) Overview of proportion of 
classical secretory proteins with a predicted SP (signal peptide) and GPI-anchor 
attachment in C. albicans secretomes. The secreted yeast and hyphal proteins were 
categorized according to their biological process using CGD Gene Ontology slim 
mapper. 
 
2.4 Peptide enrichment of Candida hyphal secretome 
Microbial secretomes consist not only of proteins, but also intracellularly 
processed peptides, which usually have important biological functions, such as anti-
microbial, hormone-like or toxin-like effects (Bischofberger et al. 2012; Los et al. 
2013). In order to investigate intracellular processed peptides and small proteins in 
the C. albicans secretome we applied solid phase extraction with C18 columns for 
peptide extraction from the culture supernatant of C. albicans hyphal cells. A total of 
16 processed proteins were identified (Supplement Table S-3). Among them, Ece1p 
was the most abundant processed protein detected in the supernatant of hyphal 
cultures. It had almost a ten times higher abundance than the second most abundant 
peptide Sap9p. The top 5 of the most abundant processed proteins were Ece1p, 
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Sap9p, Rbt1p, orf19.3004 and Sap6p (Table 6). The amino acid sequence of Ece1p 
contains eight discontinuous KR amino residues. It is predicted that they are 
recognized and processed by a Kexin-like proteinase (Bader et al. 2008). Here, all 
the eight processed peptides were detected and identified by LC-MS/MS (Figure 11). 
Among these eight processed peptides, the Ece1p-III peptide was detected as the 
most abundant peptide (Supplement Table S-3).  
Table 6 Protein list of identified processed proteins in the culture supernatant of 
C. albicans hyphal cells enriched by SPE 
Accession Description ΣCoverage Σ# Proteins Σ# Unique Peptides Σ# Peptides Σ# PSMs* 
orf19.3374 Ece1  88.56 1 54 54 256 
orf19.6928 Sap9  5.88 1 3 3 23 
orf19.1327 Rbt1 4.02 1 3 3 21 
orf19.3004 orf19.3004 12.44 1 3 3 6 
orf19.5542 Sap6 6.46 2 2 2 5 
orf19.1597 Abg1  6.25 1 1 1 4 
orf19.2452 orf19.2452  3.13 1 1 1 4 
orf19.6741 orf19.6741 3.13 1 1 1 3 
orf19.3642 Sun41 2.63 1 1 1 2 
orf19.5585 Sap5 5.5 1 1 1 1 
orf19.1442 Plb4.5  2.28 1 1 1 1 
orf19.1426 orf19.1426  2.12 1 1 1 1 
orf19.894 orf19.894 1.15 1 1 1 1 
orf19.1490 Msb2  1.06 1 1 1 1 
orf19.3681 orf19.3681  1.03 1 1 1 1 
orf19.663 Gin4  0.89 1 1 1 1 
* Σ#PSMs: the total number of identified peptide spectra matched for the protein  
Signal peptide: MKFSKIACATVFALSSQA 
Pep-I:  AIIHHAPEFNMKR 
Pep-II: DVAPAAPAAPADQAPTVPAPQEFNTAITKR 
Pep-III: SIIGIIMGILGNIPQVIQIIMSIVKAFKGNKR 
Pep-IV: EDIDSVVAGIIADMPFVVRAVDTAMTSVASTKR 
Pep-V: DGANDDVANAVVRLPEIVARVATGVQQSIENAKR 
Pep-VI: DGVPDVGLNLVANAPRLISNVFDGVSETVQQAKR 
Pep-VII: DGLEDFLDELLQRLPQLITRSAESALKDSQPVKR 
Pep-VIII: DAGSVALSNLIKKSIETVGIENAAQIVSERDISSLIEEYFGKA 
 
Figure 11 Amino acid sequence of Ece1p processed by Kex2p 
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Intriguingly, the fourth most abundant processed protein, orf19.3004 also 
contains a similar KR repeat domain and an additional Fasciclin domain (FAS) 
(Figure 12). In the KR repeat domain, each predicted by Kex2p processed peptide 
contains the KNL conserved residues at almost the same position. The FAS domain, 
which is an ancient cell adhesion domain common in plants, animals and bacteria, is 
rich in the cell entry motif KXLK (Huber et al. 1994; Ulstrup et al. 1995) (Figure 12). 
  KNIFDLESLKQGLQDEETVNNDKR 
EPVNLLYLDRFKMGVSDEAKGNAKFKR 
DPKNVIDPASLKEGSAEEEQKDKR 
EPKNLFNLQALHEGLKDEETKSKR 
EAKNLPNLEALEEALKGGSLPKK 
DAKNLIDLVALKQSLEKEAAKR 
DAKNIPDLEALKTGIEEEEGQVAKR 
DAKNVINLSNFIETPSKR 
EGKNLFDLTKFQQSGQPIKKR 
 
DQKILKQEKSLFVLNSVDCFNNLLQSILPQLSSISIFSSYIRQFASIDA 
RTANPQKVMLIVAPDNDSLETKLSDLKPWEFPEQITPEQSEQEQDKTLKNNLL
HFLNGHLINNFEENLVIDKSSTDAVTIISKLNNGKFLKIKQDQLSQKFSIRLL
DSENWIDVETIKQVENGFVLIINDSLVKP 
 
FAS Domain  
 
Figure 12 Amino acid sequence of orf19.3004 processed by Kex2p 
 
3 Immunoproteomic study of C. albicans secretome during yeast-to-hypha 
transition 
3.1 Serological response of mice to C. albicans  
3.1.1 Generation of IgG antibodies against C. albicans in mice 
In order to investigate the kinetics of C. albicans-specific IgG antibody 
generation in mice, we tested mice sera on different days after intravenous injection 
of C. albicans wildtype or mutants into the tail vein. Starting from the fifth day mouse 
sera contained C. albicans-specific antibodies in contrast to mice challenged with 
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PBS (Figure 13). This indicates that it needs at least 5 days to complete the 
production of specific IgG antibodies upon the infection with C. albicans. 
Figure 13 Generation of antibodies in time in mice upon infection with C. albicans 
wild type and virulence attenuated mutant strains. Here the number of lanes was 
marked and the used C. albicans strains were also indicated. wt: wild type; compl.: 
the correspondent complement strain, as described in Table 7. ∆: mutant strain, as 
described in the table 7. 
 
Table 7 List of mouse sera, which were used in the corresponding lanes of the 
immunoblot shown in Figure 13. The details of mouse serum samples are described 
table 3. 
Nr. 1 2 3 4 5 6 7 8 9 10 11 
Candida 
strain wt wt wt wt ssu1∆ 
SSU 
compl. 
SSU 
compl. wt 
efg∆  
cph∆ wt 
efg∆  
cph∆ 
Mice  
sera PBS 
Ca1-11 
2/8 
Ca4-11  
1/1 
Ca4-11  
2/6 
Ca1-11  
3/4 
Ca1-11  
6/7 
Ca5-11  
6/6 
Ca3-11  
1/5 
Ca3-11  
6/8 
Ca5-11  
1/3 
Ca3-11  
5/1 
  
Nr. 12 13 14 15 16 17 18 19 20 21 22 
Candida 
strain ssu1∆ cdg∆ 
CDG  
compl. wt wt wt 
CDG  
compl. 
efg∆ 
cph∆ cdg∆ 
efg∆ 
cph∆ 
efg∆ 
cph∆ 
Mice 
sera 
Ca5-11  
4/6 
Ca5-11  
8/8 
Ca5-11  
10/8 
Ca1-10  
S7 
Ca1-10  
S8 
Ca1-10  
S11 
Ca5-11  
9/5 
Ca3-11  
6/9 
Ca5-11  
7/5 
Ca3-11  
3/2 
Ca3-11  
3/4 
 
3.1.2 Serological response of mice to secreted proteins of C. albicans yeast cells 
Figure 14A shows that the IgG antibody response of mice infected with a 
C. albicans wild type (SC5314) strain for 8 days is almost as low as observed in 
control sera, which were derived from mice infected for 20 minutes. The C. albicans 
double mutant Δefg1/efg ∆cph1/cph that is unable to produce hyphae was used for 
infection experiments as well. It is characterized by an attenuated virulence 
(Samaranayake et al. 2013). Mice infected with this mutant strain survived and a 
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strong serological response directed against C. albicans yeast secreted proteins after 
20 days of infection was elicited (Figure 14C). However, it differed from the 
responses observed in candidemia patients. Since C. albicans is a common 
commensal in humans, but not in mice, strong IgG antibody signals were detectable 
against the C. albicans yeast secretome even in healthy humans (Figure 14B). In 
most of candidemia patients, the serological anti-C. albicans IgG antibody profiles are 
more complex and variable in comparison to healthy individuals. In both healthy 
human individuals and candidemia patients, Mp65p and ß-glucanase Xog1p were 
identified as the dominant immunoreative antigens in this study (Figure 14B).  
 
 
Figure14 Exemplary 2D immunoblot overlays for the comparison of the serological 
response of mice and candidemia patients to the C. albicans yeast secretome. A: 2D 
immunoblot overlays for the serological response of mice to the C. albicans yeast 
secretome after 8 days infection in comparison to control mouse sera collected after 
20 minutes infection with C. albicans wild type strain; B: Comparison of the 
serological response of mice systemically infected with C. albicans mutant strain 
Δefg1/efg ∆cph1/cph with control mouse sera described in A); C: Comparison of the 
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serological response of candidemia patients to the C. albicans yeast secretome with 
control serum from healthy blood donor. 
 
3.2 Mapping of the C. albicans immunosecretome in candidemia and non-candidemia 
patient groups 
To investigate the human host-specific serological response to the C. albicans 
secretome, sera samples from candidemia patients were compared with sera 
samples from SIRS patients, bacteremia (without fungal infection) and patients 
without suspected infection by applying serological proteome analysis (SERPA), 
which combines 2D-gel electrophoresis with immunoblotting. Details about the sera 
samples used are listed in Table 4. In Figure 15, C. albicans yeast and hyphal 2-D 
immunoblot overlays are exemplarily shown, which demonstrate the differences in 
antigen recognition of secreted proteins by human IgGs from sera of the different 
patient groups described above. 
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Figure 15 C. albicans yeast and hyphal secretomes recognized by serum IgG 
antibodies from candidemia and non-candidemia patients groups. 2-D immunoblot 
overlays show the differences in the C.albicans yeast and hyphal secretome antigen 
recognition profiles from representative patients of each sera sample group. A) 
Candidemia patient; B) SIRS patients; C) bacteremia patients; D) negative control 
(patients above 60 years without suspected infection). Blue-coloured images 
represent detected protein spots and orange-coloured images show Western blot 
signals from the anti-C. albicans antibodies in patients´ sera. The identified proteins 
are indicated. 
 
3.3 Sera IgG titer assay of candidemia and non-candidemia control groups in 
response to C. albicans hyphal secretome 
The titers of sera IgGs directed against the C. albicans hyphal secretome in 
candidemia and non-candidemia patients were determined by ELISA. The median 
values of anti-C. albicans IgG titers in sera of sepsis patients were much higher than 
in the other control groups. Nevertheless, the highest anti-C. albicans IgG titer in the 
control group of patients without suspected infection and in the SIRS group were as 
high as the level observed in sepsis patients. The lowest anti-C. albicans IgG titer in 
the sera of sepsis patients was as low as the level determined in healthy, voluntary 
donors (Figure 16A). Figure 16B shows that the median values of anti-C. albicans 
IgG titers in candiduria patients and candidemia patients with other than C. alibcans 
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species infection were only a little lower than in candidemia patients with only 
C. albicans infection. Candiduria patients were diagnosed by the detection of 
C. albicans in the urine culture. The anti-C. albicans IgG titer fluctuated considerably 
in the sera of sepsis patients with both bacterial infection and candida infection 
(Blood F+B) as well as SIRS patients with acute pancreatitis (SIRS A.P.).  
   
Figure 16 ELISA assay of the anti-C. albicans IgG titer in sera of candidemia and 
non-candidemia patients. Blood F: sera samples positive for C. albicans in the blood 
culture; Blood F+B: sera samples positive for C. albicans and bacteria positive in the 
blood culture; Blood C. spp: sera samples positive for C. spp. in the blood culture; 
Urine: urine samples positive for C. albicans; Pus: C. albicans were detected in the 
pus samples; SIRS (A.P.): acute pancreatitis patients without suspected systemic 
infection  
 
3.4 Serological profiles of IgG antibodies directed against C. albicans secreted 
proteins 
Despite the high heterogeneity of the protein antigen recognition patterns by 
patient IgG antibodies, 20 different protein antigens were frequently detected by sera 
of candidemia patients. A total of two yeast-specific and 17 hyphal-specific secreted 
proteins were identified as immunoreactive in at least four out of five patients with 
candidemia. However, they all showed serum-positive antigenicities in other non-
candidemia patients groups as well (Table 8). In addition, one secreted protein, the 
β-glucanase Xog1p, recognized by sera in the secretomes of hyphal C. albicans 
cells, was also recognized by three serum samples out of five candidemia patients in 
the yeast secretome.  The protein antigens´ functions were mainly associated with 
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stress responses (G-beta-like protein Asc1p, Elongation Factor 2 Eft2p, likely 
cobalamin-independent methionine synthase Met6p, putative vacuolar protease B 
Prb12p and two likely thioredoxin peroxidases Prx1p and Tsa1p), carbohydrate 
metabolism (pyruvate kinase Cdc19p, triose-phosphate isomerase Tpi1p, enolase 
Eno1p, fructose-bisphosphate aldolase Fba1p, aconitase Aco1p, putative pyruvate 
carboxylase Pyc2p, transaldolase Tal1p, putative transketolase Tkl1p, alpha-
glucosidase Rot2p and exo-1,3-beta-glucanase Xog1p) and lipid degradation (lipase 
Lip4p and phospholipase B Plb4.5p) (Table 8).  
Table 8 Analysis of the IgG antibody response against C. albicans extracellular 
proteins in candidemia patients and control groups.  
 
Identified C. albicans antigens 
Serum IgG response to C. albicans 
proteins  
No. of seropositive patients 
Ab. response 
reported in 
Name   CGD accession 
Yeast  
Ag. 
Hyphal  
Ag. 
Candidemia     
(n= 5) 
SIRS  
(n=5) 
Bacteremia 
(n=5) 
Neg. 
control 
(n=6) 
 mice  human 
Reponse to stress 
Asc1 orf19.6906 
 
√ 4 1 2 2 / Y12 
Eft2 orf19.5788 
 
√ 5 5 5 4 Y12;13 Y12;13 
Met6 orf19.2551 
 
√ 5 4 2 0 Y13;17;18 Y13;17;18 
Prb12 orf19.7196 
 
√ 5 5 3 3 / / 
Prx1 orf19.5180 
 
√ 4 1 1 3 / / 
Tsa1 orf19.7417 
 
√ 4 2 0 3 Y13;15 / 
Proteases and lipases 
Lip4 orf19.2133 √ 
 
5 3 5 4 / / 
Plb4.5 orf19.1442 √ 
 
5 5 5 6 / / 
Carbohydrate metabolic process 
Cdc19 orf19.3575 
 
√ 4 2 2 3 Y11;13;15 / 
Tpi1 orf19.6745 
 
√ 4 2 1 2 Y11-15 Y11-15 
Eno1 orf19.395 
 
√ 5 4 4 3 Y14 Y16 
Fba1 orf19.4618 
 
√ 5 1 3 2 Y11-13 Y11-13 
Aco1 orf19.6385 
 
√ 4 4 1 1 Y11;12 Y11;12 
Pyc2 orf19.789 
 
√ 5 5 5 4 / / 
Tal1 orf19.4371 
 
√ 4 4 3 3 / / 
Tkl1 orf19.5112 
 
√ 5 5 4 6 Y12;13 Y12;13 
Rot2 orf19.974 
 
√ 5 5 3 4 / / 
Xog1 orf19.2990  √ 5
H; 3Y 5
H; 
2Y 3
H; 3Y 6H; 5Y / / 
Unknown function 
Ssp120 orf19.3173   √ 4 2 1 0 / / 
Superscript numbers in the table refer to references that reported the antibody response to specific C. 
albicans proteins in mice or humans.  Superscript H stands for hypha; Superscript Y stands for yeast. 
  Results 
42 
 
3.5 Glycosylation of secreted proteins has a significant effect on the antigen 
recognition by IgG antibodies 
3.5.1 Glycosecretome 
To investigate whether C. albicans secreted hyphal proteins are modified by 
glycosylation, the periodic acid-schiff (PAS) method was applied for the staining of 
C. albicans extracellular glycoproteins. Mp65p and Sap6p turned out to be the most 
heavily glycosylated proteins in the C. albicans hyphal secretome (Figure 17).
 
Figure 17 PAS-glycostaining of 2-D hyphal secretome gel (A) was followed by 
Coomassie staining (B) for total protein detection. 
 
3.5.2 Dependence of the immunoreactivity of Sap6p on the glycosylation status 
In order to investigate whether glycosylation plays a critical role in the 
recognition of protein antigens by IgG antibodies, oligosaccharide residues were 
removed from extracellular proteins by enzymatic treatment using a commercial 
deglycosylation kit. Figure 18A and 18C illustrate that deglycosylation leads to 
changes of the isoelectric point and molecular mass of several proteins. The anti-
Sap6p antibody signal was drastically reduced after deglycosylation (Figure 18B and 
18D). This indicates that sugar residues of Sap6p are major part of the epitope that is 
recognized by patient’s anti-Sap6p antibodies. Moreover, also Mp65p and other cell 
wall proteins in the upper-left corner showed reduced antibody levels in candidemia 
patients after deglycosylation. 
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Figure 18 Immunoreactivity of Sap6p in sera of candidemia patients after 
deglycosylation. 2D membrane images of an untreated C. albicans hyphal secretome 
sample (A) and a deglycosylated C. albicans hyphal secretome sample (C); B) and 
D) show the corresponding Western blot signals of IgG serum antibodies from one 
representative candidemia patient, respectively. In the top left-hand corner of B) and 
D), the excised left corners represent mainly the patient sera antibody response 
against C. albicans mannoprotein Mp65p. 
 
3.5.3 Glycosylation of recombinant Sap6p 
             To investigate the importance of Sap6p glycosylation for antigen recognition 
in more detail, we used a recombinantly produced Sap6p that had been 
heterologously expressed in Pichia pastoris. In Figure 19B recombinant Sap6p was 
separated in four bands after SDS-PAGE (ca. 62 kD, 40 kD, 30 kD and 10 kD). 
These four bands were all identified as Sap6p by MALDI-TOF/TOF. The smaller 
bands of 30 kD and 10 kD most likely represent self-proteolytic products of Sap6p 
(40 kD). The Sap6p protein bands with a respective molecular mass of 62 kD, 40 kD 
and 30 kD were differentially glycosylated (Figure 19A). The degree of glycosylation 
decreased apparently from the 62 kD band to 30 kD band. After deglycosylation, the 
apparent molecular masses of the 40 kD and 30 kD bands of Sap6p decreased. By 
contrast, no shift was observed for the 62 kD band after deglycosylation (Figure 19A 
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and B). The 62 kD band may represent a dimer due to incomplete denaturation. Its 
steric conformation may prevent enzymatic deglycosylation.  
 
 
Figure 19 Identification of protein glycosylation in the secretome of C. albicans 
hyphal cells and the recombinant Sap6p protein A) Staining of the C. albicans 
secretome of hyphal cells and the recombinant Sap6p protein (expressed in 
P. pastoris) based on the periodic acid-Schiff (PAS) reaction. B) Post-staining of the 
gel shown in A) with Coomassie Blue for the global visualization of separated protein 
bands (comparison of glycoproteins with non-glycosylated proteins). 
 
3.5.4 Immunoreactivity of recombinant Sap6p in sera of candidemia patients after 
deglycosylation of Sap6p 
Although the serum antibody response to recombinant Sap6p showed a highly 
interindividual variety among the patients´ groups, deglycosylated recombinant 
Sap6p proteins were hardly recognized by anti-Sap6p serum antibodies from all sera 
species, including four candidemia, two SIRS, two bacteremia patients and four 
negative controls (two patients without infection and two healthy blood donors) 
(Figure 20). Notably, after deglycosylation, the intensity and molecular mass of the 
62 kD band did not change. Altogether our experiments with the recombinant Sap6p 
confirmed that glycosylation of Sap6p plays an important role in its recognition by 
anti-Sap6 antibodies. 
  Results 
45 
 
 
Figure 20 Comparative analysis of the recognition of the recombinant C. albicans 
Sap6p antigen by serum antibodies from candidemia and non-candidemia patients 
before and after deglycosylation treatment  
IC: invasive candidiasis; SIRS: systemic inflammatory syndrome; Bac: bacteremia; Neg.: 
negative control; LM: healthy donor (lab member); un: untreated sample; deg: deglycosylated 
sample; M: molecular mass marker proteins 
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Discussion 
During yeast-to-hypha transition Candida albicans secretes numerous proteins 
for nutrition acquisition, tissue damage and modulation of the immune response 
(Naglik et al. 2004; Schaller et al. 2005). The aim of the present work was to 
investigate the dynamics of the C. albicans secretome composition during the yeast-
to-hypha transition as well as its ability to elicit serological responses in candidemia 
patients. 
Several studies have analyzed the global protein composition of the 
C. albicans secretome including the content of secreted extracellular vesicles under 
different growth conditions by LC-MS/MS (Sorgo et al. 2010; Sorgo et al. 2011; Ene 
et al. 2012; Gil-Bona et al. 2015). Here, we characterized the secretomes of yeast 
and hyphal cells of C. albicans by combining two proteomic approaches, i.e., 2D-gel 
electrophoresis and mass spectrometry-based proteomics, to deliver a 
comprehensive picture of the set of secreted proteins. Furthermore, an 
immunoproteomic approach was applied to identify C. albicans extracellular protein 
antigens, which provoke a potent antibody response in patients with candidemia. 
 
1 Qualitative analysis of C. albicans yeast and hyphal secretome during the 
yeast-to-hypha transition 
1.1 Comparison of gel-based with gel-free proteomic approach 
By combining two proteomic approaches, 101 different secreted yeast and 410 
hyphal proteins were identified (Table S-1). Several secreted proteins were detected 
in the culture supernatant for the first time, like some cell wall proteins (Cdc3p, 
Exg2p, Hyr1p and Mnt2p), secreted proteases (Ape3p, Cpy1p), adhesin (Als1p) and 
lipases (Lip4p and Plb2p). The majority of the detected proteins were identified by 
LC-MS/MS (92 % of identified yeast proteins and 95 % of hyphal proteins), whereas 
8 yeast and 19 hyphal proteins were exclusively detected by 2D gel electrophoresis. 
This may be explained by the technical limitation of 2D gel electrophoresis to 
separate hydrophobic, low abundant, small and high molecular mass proteins and 
proteins with extreme pI (Aebersold et al. 2003; Speers et al. 2007; de Godoy et al. 
2008; Kniemeyer et al. 2011). However 2D-GE provides an overview about the 
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features of individual, intact proteins including PTMs. It is particularly suitable for 
antigen identification by combining 2D-GE with immunoblotting. 
 
1.2 Classical secreted proteases, lipases and adhesins 
During yeast-to-hypha transition the C. albicans secretome undergoes 
significant dynamic changes. We found that some members of the Sap family, 
agglutinin-like sequence (ALS) family or lipases were detected either exclusively in 
the supernatant of yeast or hyphal cells (Table 11). It is well known, that the pH 
strongly affects expression of different SAP genes (Remold et al. 1968; Ruchel 1981; 
Morrison et al. 1993; White et al. 1993; Smolenski et al. 1997; Borg-von Zepelin et al. 
1998). Indeed, we detected Sap2p, Sap3p and Sap10p, whose functional activities 
are optimal at pH3-5, exclusively in yeast cell cultures. By contrast, the hypha-
associated proteases Sap4p, Sap5p and Sap6p were reported to be active at a 
higher pH of 5-7 (Naglik et al. 2003), and accordingly they were only detected in the 
medium supernatant of hyphal cells.  
Table 11 Summary of identified lytic enzymes and proteins involved in cell wall 
organization  
 
Secreted 
proteases Adhesins Lipases Chitinases 
Cell wall 
organization 
Yeast 
specific Sap2, Sap3, Sap10 Als2, Als4 Lip4 Cht1 
Phr2, Pir1, Ssu81, 
Sur7, Orf19.6741 
Hyphae 
specific Sap4, Sap5, Sap6 Als1, Als3   
Abg1, Act1, Kre5, 
Mnt2, Phr1, Pmi1, 
Rbt1, Sod1, Tsa1, 
Orf19.2677 
Common 
in yeast 
and hypha 
Sap7, Sap9 
 
Plb4.5 Cht2, Cht3 
Bgl2, Crh11, Ecm33, 
Kex2, Mnt1, Msb2, 
Pga4, Rhd3, Rho1, 
Sim1, Sun41, Utr2, 
Xog1, Yps7 
 
1.3 Cell wall-associated proteins 
Many cell wall proteins were detected in the C. albicans yeast and hyphal 
secretome. This result is also consistent with Sorgo´s study (2010), which found 
approximately 57 % of detected secreted proteins to be cell wall-related (Sorgo et al. 
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2010). This finding suggests that cell wall-bound proteins are partially released from 
the fungal cell walls during growth. In this study, more than half of the identified 
proteins, which are involved in cell wall organization, were found in both culture 
supernatants of yeast cells and hyphae. These proteins include chitinases (Cht2p, 
Cht3p), chitin transglycosylases (Crh11p, Utr2p), glucanosyltransferases (Bgl2p, 
Pga4p), glucanases (Xog1p, Sim1p and Sun41p) and lytic enzyme (Sap9p) (Table 
11). Also, many proteins exclusively detected in yeast or hyphal cell walls were found 
in this study, like the yeast-associated proteins Phr2p and Pir1p as well as the hypha-
associated proteins Act1p, Kre5p, Phr1p, Rbt1p, Sod1p and Tsa1p. Based on GO-
Slim annotation (Candida Genome database), these hypha-associated proteins are 
mainly involved in the response to alkaline environments, like Phr1p, Rbt1p and 
Sod1p, oxidative stress, such as Act1p, Sod1p and Tsa1p, or contribute to virulence, 
for example Kre5p, Mnt2p, Phr1p, Rbt1p and Sod1p. This suggests that hypha cells, 
in contrast to yeast cells, are likely under alkaline pH and oxidative stress conditions 
and become invasive to host cells. Hyphal cell wall proteins presented in the medium 
supernatant are highly regulated by these stress stimuli and correlate with the 
pathogenic program. This could also be explained by some cell wall proteins 
detected in this study, such as Sod1p, Rbt1p and Phr1p, which are inducible by the 
stress stimuli and also involved in virulence. 
 
1.4 Non-conventional secretory proteins 
Notably, only 107 out of 446 secreted proteins carry an in silico predicted 
signal peptide for secretion. A large number of non-canonical secretory proteins (339) 
were present in the medium supernatant, particularly of hyphal cells. These cytosolic 
proteins lacking a secretion signal are mostly associated with carbohydrate 
metabolism, response to stress and translation. They may represent ’moonlighting’ 
(multifunctional) proteins as previous secretome studies of Saccharomyces 
cerevisiae, C. albicans and several bacteria postulated (Nombela et al. 2006; Gil-
Bona et al. 2015; Gotz et al. 2015). Notably, 6 and 15 proteins mediating vesicle-
transport were detected in yeast and hyphal secretomes, respectively, which 
indicates that membrane vesicles may drive this unconventional protein secretion. In 
support of these findings, Ana et al. and Gabriele et al. recently reported that 
cytoplasmic proteins of C. albicans are transported via extracellular vesicles to the 
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outside (Gil-Bona et al. 2015; Vargas et al. 2015). It was shown that Eno1p, Rho1p, 
Tdh3p, Pdc11p, and Ypt31p were present in extracellular vesicles of C. albicans 
yeast cells. These proteins were also detected in this present study. Besides, Sorgo 
found that most cytosolic proteins were only detected in the supernatant of hyphal- 
and fluconazole-treated cells (Sorgo et al. 2011), which indicates that the export of 
proteins without obvious signal sequence is highly regulated by environmental 
stimuli. Alternatively, they could have been released due to the lysed cells within a 
natural population of cells. 
In summary, the basic composition of C. albicans proteins, contributing to the 
maintenance of the cell wall, is similar in yeast and hypha. By contrast, extracellular 
proteins connected to stress responses differ substantially between the two 
morphotypes. 
 
2 Quantitative analysis of C. albicans yeast and hyphal secretomes 
The quantitative analysis of C. albicans yeast and hyphal secretomes via TMT 
labeling has shown that only 7 proteins are two-fold more abundant in yeast than in 
hyphae, whereas 155 proteins are two-times enriched in hyphal cells compared with 
yeast cells. This indicated that C. albicans cells secrete significantly more proteins 
with high abundance during the yeast-to-hypha transition. This result is also 
consistent with the qualitative analysis of the C. albicans secretome. The detected 
proteins, which were shared by both yeast and hyphal cells, are mainly cell wall 
proteins, proteases, adhesins, chitinases and lipases. Notably, several proteins, 
which were identified only in one morphotype in the qualitative analysis of 
secretomes, are still detectable in the quantitative analysis with TMT labeling. For 
example, Pir1p protein is a basic cell wall structure protein of C. albicans. It has been 
reported that the expression of PIR1 is repressed by Rim101p and downregulated in 
hyphae (Sohn et al. 2003; Lotz et al. 2004). In the quantitative analysis shown here, 
Pir1 was detected as a protein with higher abundance in yeast cell than in hypha, 
whereas it was only detectable in yeast but not hypha in our qualitative study. The 
explanation for that could be, that some morphologically regulated proteins are just 
enriched in one morphotype and very low abundant in the other (maybe below 
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detection limit). To quantify the relative protein abundance, the TMT-labeling 
approach is more reliable than a label-free approach using spectral counting. 
3 Peptide analysis in the Candida hyphal secretome 
Besides intact extracellular proteins, intracellularly proteolytic processed 
peptides are also detectable in the culture supernatant of C. albicans hyphal cells. 
Here, it was demonstrated that Ece1p was the most abundant processed protein 
among all SPE-enriched peptides. This finding is also in line with the transcriptional 
expression of C. albicans hyphal cells, which indicated that ECE1 was highly 
expressed during hyphal growth (Birse et al. 1993). It is known that Ece1p is 
processed by the protease Kex2p into eight peptides (Bader et al. 2008). Among 
them, the peptide III turned out to be the most dominant peptide in the culture 
supernatant based on the LC-MS/MS analysis. The C. albicans peptide Ece1p-III has 
recently been shown to represent a cytolytic peptide toxin, the first described peptide 
toxin in a human pathogenic fungus (unpublished data, Moyes et al.). It is only 
produced by the invasive hyphal form of C. albicans. The Ece1p-III peptide is an 
amphipathic molecule. It has a positively charged C-terminus, which is required for 
membrane permeability and triggers an inward current concomitant with calcium 
influx. It possesses also a hydrophobic transmembrane domain with an α-helical 
structure for cytolysis of multiple human epithelial cell types. It was demonstrated that 
the Ece1p-III peptide directly damages epithelial membranes, by triggering p-
MKP1/c-Fos mediated danger response pathway and secreting the anti-inflammatory 
cytokines for activating epithelial immunity (unpublished data, Moyes et al.). 
 
4 Serological response of mice to C. albicans yeast secreted proteins  
Although C. albicans is not a commensal on the mucosal surface of mice, 
mouse models of invasive C. albicans infection by intravenous injection are still the 
most popular method to assess Candida virulence until today (Maccallum 2012). 
Besides determining virulence, mice models of systemic candidiasis allow also 
characterizing the serological response to C. albicans. One of the results of studying 
the serological response in mice, which are shown here, is that the generation of C. 
albicans-specific IgG antibodies takes at least five days upon infection. Secondly, the 
serological responses to secreted proteins of C. albicans yeast cells during systemic 
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infections are less pronounced and diverse in comparison to humans. This may be 
explained by the fact, that C. albicans, in contrast to mice, is a normal constituent of 
the human flora, which leads to a basal anti-C. albicans antibody level in human sera. 
The second reason for the differences may lay in the fact that mouse antibody IgG 
subclasses differ from human IgG subclasses, which might cause different antibody 
responses (Mestas et al. 2004). Thirdly, human sera may contain more cross-
reacting IgG antibodies due to complex disease background and a heterogenous 
gastrointestinal flora, which could induce the production of cross-reactive antibodies 
that recognize C. albicans antigens. 
 
5 Serological profiles of human IgG antibodies directed against C. albicans 
secreted proteins 
As shown here, IgG antibodies directed against C. albicans are generally 
detectable in human sera, albeit showing weak and delayed antibody responses in 
some patients. To get a deeper insight into the antibody response against secreted 
proteins of C. albicans, an immunosecretome reference map of C. albicans was 
established by screening sera of systemic candidemia patients using a gel-based 
proteomic approach. 
 
5.1 Comparison of C. albicans yeast immunosecretome with hyphal 
immunosecretome in candidemia patients 
Altogether, two yeast and 17 hyphal secreted immunogenic proteins were 
identified. This finding implied that hyphal cells elicited a stronger antibody response 
than yeast cells possibly due to the fact, that the hypha is the invasive morphotype of 
C. albicans (Gow et al. 2012) (Table 8). This finding fits well with many other in vitro 
and in vivo studies which showed that the hyphal form of C. albicans invades 
epithelial and endothelial cells and causes damage, in particular by the release of 
hydrolytic enzymes and toxic peptide (Scherwitz 1982; Filler et al. 2006; Phan et al. 
2007; Dalle et al. 2010; Zhu et al. 2010; Sudbery 2011; unpublished data, Moyes et 
al.). The immunogenic proteins we identified mainly included proteins in response to 
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oxidative stress, starvation stress, heat and drug stress (Asc1p, Eft2p, Met6p, 
Prb12p, Prx1p and Tsa1p), lytic enzymes (Lip4p and Plb4.5p), cell wall 
polysaccharide and glucose metabolism-associated proteins (Cdc19p, Tpi1p, Eno1p, 
Fba1p, Aco1p, Pyc2p, Tal1p, Tkl1p, Rot2p and Xog1p). Among them, 9 antigens 
have already been reported by Pitarch et al. (Pitarch et al. 2004). They all represent 
abundant housekeeping proteins (Aco1p, Asc1p, Eft2p, Eno1p, Fba1p, Met6p, Tkl1p, 
Tpi1p and Tsa1p), localized in the cytoplasm, but all are also detectable in the 
extracellular space. This finding indicates that these housekeeping enzymes also 
play a role outside the cell wall and interact with the host immune cells. 
In this study, nine proteins (Prb12p, Prx1p, Lip4p, Plb4.5p, Pyc2p, Tal1p, 
Rot2p, Xog1p and Ssp120p) have been described to be immunogenic for the first 
time. Intriguingly, C. albicans yeast cells secreted two lipases, e.g., lipase Lip4p and 
phospholipase Plb4.5p, triggered antibody production during systemic candidiasis. 
They both represent extracellular lipolytic enzymes, which may contribute to host 
tissue invasion by degrading host surface molecules and destroying cell membranes. 
It has been reported that C. albicans phospholipase B is secreted to a higher amount 
by a C. albicans strain isolated from human blood than from a commensal strain 
(Ibrahim et al. 1995; Schaller et al. 2005). Furthermore, the LIP4 gene was reported 
to be expressed during the early phase of systemic liver infection in mice and in 
samples of patients with oral candidiasis (Stehr et al. 2004). 
 
5.2 Comparison of serological response of candidemia patients and non-candidemia 
patient groups directed against C. albicans secretome  
The anti-C. albicans antibody levels in candidemia patients are in most cases 
higher than in non-candidemia control groups (Figure 15). In line with this finding, 
ELISA tests for sera IgG titer against the C. albicans hyphal secretome showed that 
the median value of the IgG titer against C. albicans hyphal secretome was much 
higher in sepsis patients than in control patients. However within the patient groups 
the anti-C. albicans antibody levels differed strongly. Notably, patients with a positive 
detection of C. albicans in urine samples also showed a strong serological response 
against secreted proteins of C. albicans as observed for candidemia patients. This 
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suggests that for the diagnosis of systemic candidiasis not only blood cultures, but 
also urine samples may be an additional indicative tool.  
 
5.3 Serum levels of specific anti-C. albicans antibodies help to diagnose systemic 
candidiasis 
The results reported here give ample reason to assume that there is no clear, 
unambiguous picture of an anti-C. albicans antibody pattern in candidemia patients. 
Since C. albicans is a commensal in most humans and surface infections occur 
frequently, a basal level of anti-C. albicans antibodies is present in most individuals. 
However, seven C. albicans extracellular antigens (Xog1p, Rot2p, Eno1p, Met6p, 
Tsa1p, Tpi1p and Prx1p) contribute to distinguish candidemia from bacteremia, SIRS 
and control patients. The mean level of the serological antibody response to each of 
these seven antigens is at least two fold higher in candidemia patients than in the 
other three control groups. For this reason, they may represent promising biomarkers 
for the diagnosis and prognosis of candidemia. Interestingly, the top 7 serodominant 
antigens of C. albicans (Xog1p, Rot2p, Eno1p, Met6p, Plb4.5p, Tkl1p and Tal1p) 
were also recognized by sera of SIRS and bacteremia patients (Table 12). Less 
immunoreactive proteins (antigens with low level of detection signals on immunoblot) 
showed, however, often less or no cross-reaction with sera of control groups (Table 
12). Presumably, an unspecific epitope, which is shared by many immunogenic 
proteins, triggers antibody responses in patients with systemic inflammation including 
candidemia, SIRS and bacteremia. A common feature of these seven serodominant 
antigens is that they are localized in the extracellular space (based on their GO-Slim 
Mapper annotations categorized by the cellular components). It is well known that 
most C. albicans extracellular proteins are glycosylated (Delic et al. 2013; Hall et al. 
2013). Furthermore polysaccharides are common dominant antigens on the cell 
surface of C. albicans, such as mannans and ß-glucans (Hasenclever et al. 1961; 
Chattaway et al. 1968; Poulain et al. 1985; Nelson et al. 1991). Therefore, these 
proteins most likely share glyco-epitopes or, alternatively, conserved amino acid 
sequences, which trigger antibody responses in patients with systemic inflammation. 
Notably, anti-Plb4.5p antibody levels were consistently high in all patient 
groups, which indicate that the yeast-specific phospholipase Plb4.5p may represent a 
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highly abundant, secreted protein antigen of C. albicans yeast cells. The C. albicans 
secretome data also showed that Plb4.5p was among the top 5 abundant proteins in 
the yeast secretome when its peptide-spectrum matching (PSM) score was 
considered. Thus, Plb4.5p may confer a vital and basic biological function during host 
colonization, like nutrition acquisition by hydrolysis of ester linkages in 
glycerophospholipids from host tissues. In support of this finding, a C. albicans 
surface protein microarray showed that the mean antibody signal intensities to the 
top-forty serodominant antigens were slightly higher in healthy individuals than in 
non-infected hospital patients and acute candidemia patients (10,380 vs. 8,837 and 
8,825, respectively) (Mochon et al. 2010). This suggests that a continuous interplay 
between the human host and C. albicans exists. 
Table 12 Heat map of signal intensity of serum antibodies binding to the C. albicans 
secreted protein antigens. The colors red, orange, yellow, light green, dark green 
illustrate signal intensities ranging from very strong (red) to no signal (dark green). 
The antibody response signals were classified according to the grey intensity of spot 
signals in the class 3 (strong signal), 2 (middle), 1 (weak/no signal). Later, the 
average value of each antigen signal in each patient group was summarized. 
Protein 
 
Name   
Yeast 
antigens 
Hyphal 
antigens 
SP Candidemia     
(n= 5) 
SIRS 
(n=5) 
Bacteremia 
(n=5)  
Neg. 
control 
(n=6) 
Xog1   √ √ 3 1.6 1.6 1 
Rot2  √ √ 3 1.8 1.4 0.6 
Eno1 
 
√ 
 
2.8 1.4 1.4 1 
Met6 
 
√ 
 
2.8 1.8 0.8 0 
Plb4.5 √ 
 
√ 2.6 2.6 2.8 2.6 
Tkl1 
 
√ 
 
2.4 2.4 1.4 1.6 
Tal1   √   2.4 2 0.6 1.2 
Tsa1   √   2 0 0.4 0.5 
Tpi1 
 
√ 
 
2 0.4 0.2 0.5 
Eft2 √ 
 
1.8 1.6 1.6 0.6 
Pyc2  √ 
 
1.8 2.2 2.4 0.6 
Prx1 
 
√ 
 
1.6 0.2 0.2 0.5 
Prb12 
 
√ √ 1.4 2.2 0.6 0.6 
Lip4 √ 
 
√ 1.4 0.6 1 0.8 
Aco1   √   1.2 1.6 0.2 0.2 
Cdc19   √   1 0.4 0.4 0.6 
SSP120 
 
√ √ 1 0.4 0.2 0 
Fba1 
 
√ 
 
1 0.2 1 0.3 
ASC1   √   0.8 0.2 0.4 0.4 
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5.4 Effect of glycosylation of secreted proteins on the antigen recognition 
Glycoprotein staining of the C. albicans hyphal secretome showed that many 
secreted proteins were glycosylated. In particular the secreted protease Sap6p was 
highly glycosylated (Figure 17). This is in line with the fact that C. albicans Sap6p has 
been reported to be N-glycosylated (Aoki et al. 2011). C. albicans Sap6p was hardly 
recognized by serum antibodies after enzymatic removal of N- and O-glycans of  
hyphal secreted proteins of C. albicans or the recombinantly-produced Sap6p protein 
(Figure 18 and 19). It is therefore reasonable to conclude that the carbohydrate 
moiety of Sap6p represents a major epitope and is critical for triggering serological 
responses. A recent study strongly supports this finding. Hao et al. demonstrated that 
C. albicans Sap6p contains the adhesion motif RGD to bind integrins on epithelial 
cells, which results in the internalization of Sap6p to endosomes and lysosomes (Wu 
et al. 2013). Finally, this leads to the apoptosis of epithelial cells. Moreover, Sap6p 
was reported to be able to induce activation of the inflammasome in human 
monocytes and murine macrophages, which finally leads to innate immune cell 
activation (Pietrella et al. 2013; Gabrielli et al. 2015). Thus, it is conceivable, that 
Sap6p activity further mediates the adaptive immune response including the 
production of specific anti-Sap6p antibodies.  
Intriguingly, serum anti-Sap6 antibodies were not only detected in candidemia 
patients, but also in sera of control groups including SIRS and bacteremia patients as 
well as patients without suspected infection. It is likely that the glyco-epitope of 
Sap6p is recognized by antibodies that are not specific for Sap6p. This glyco-epitope 
may share significant structural similarities with glyco-epitopes of other proteins or 
microorganisms. Secondly, although blood cultures in all non-candidemia control 
patients (SIRS, bacteremia and patients without suspected infection) were negative 
for C. albicans, a past episode of a transient or local invasive candidiasis in control 
patients cannot be excluded (Ostrosky-Zeichner 2012). In addition, an increased 
exposure to C. albicans due to translocation across the gut mucosa was observed in 
bacteremia and may also occur in SIRS patients (Otto et al. 2011). 
Not only C. albicans Sap6p, but also many other secreted proteins showed 
considerably reduced sera antibody responses after deglycosylation treatment 
(Figure 18). For example, Mp65p, which is one of the most immunodominant 
antigens of C. albicans, was obviously much less immunoreactive after 
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deglycosylation (Figure 18B and 18D). However the serological antibody responses 
to some other protein antigens were not influenced after deglycosylation, which 
suggests the presence of peptide epitopes. These antigens mainly include abundant 
housekeeping proteins such as the serodominant antigens Met6p and Eno1p. In 
short, these findings implicate that glycosylation of extracellular proteins plays a 
critical role in the antibody response of C. albicians-infected patients. However, 
antibody responses directed to many cytosolic proteins are likely mediated by peptide 
epitopes. Furthermore, this study provides evidence that the serological response to 
glyco-epitopes of extracellular proteins allows distinguishing candidemia patients 
from negative controls despite the fact that glyco-epitopes was not species-specific 
and show cross-reactivity.  
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Conclusion 
           In this study, the secretome of Candida albicans during the yeast-to-hypha 
transition was qualitatively and quantitatively analyzed. The identified C. albicans 
secreted proteins mainly included cell wall-associated proteins, proteins in response 
to environmental stimuli, secreted proteases, lipases and adhesins as well as 
carbohydrate metabolism-associated proteins. In comparison to the yeast form, 
hyphal cells undergo cell wall remodeling and release significantly more proteins into 
the extracellular milieu. However, yeast cells share many common proteins with 
hyphal cells, which constitute the basic cell wall structure and function of C. albicans 
cells. Besides, intracellularly proteolytic processed, secreted peptides play an 
important role in the interplay with host cells. Peptide Ece1p III is the most abundant 
peptide in the supernatant of C. albicans hyphal culture. It has been identified as the 
first fungal cytolytic peptide toxin, which can directly damage epithelial cells, and 
consequently is crucial for mucosal invasion (unpublished data, Moyes et al.). 
Extracellular proteins of C. albicans are accessible targets of the host immune 
system. The in-depth investigation of the serological response against secreted yeast 
and hyphal proteins of C. albicans in candidemia patients and three control groups 
(SIRS, bacteremia and patients without suspected infection) revealed a core set of 20 
immunodominant anti-C. albicans secreted protein antibodies. Nine proteins (Prb12p, 
Prx1p, Lip4p, Plb4.5p, Pyc2p, Tal1p, Rot2p, Xog1p and Ssp120p) have been 
described to be immunogenic for the first time. Seven proteins represent potential 
diagnostic markers for candidemia (Xog1p, Rot2p, Eno1p, Met6p, Tsa1p, Tpi1p and 
Prx1p). Certainly, further studies are required for the validation of the determined 
antibody signatures. 
Furthermore, glycosylation of C. albicans extracellular proteins not only 
enhanced the immunogenicity, but also induced unspecific binding of antibodies, 
leading to cross-reactivity of C. albicans antigens. Therefore, the identification of the 
immunogenic carbohydrate moiety, the so-called glyco-codes, which stimulates the 
antibody response in candidemia patients, could serve as a basis for the 
development of a new diagnostic assay or therapeutic vaccines.  
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Supplements 
 
Figure S-1. Scatter plot of pO2, stirring rate, pressure, CO2 evolution and sodium 
hydroxide consumption during an 18 h cultivation of C. albicans yeast cells. 
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Figure S-2. Scatter plot of pO2, stirring rate, pressure, CO2 evolution and sodium 
hydroxide consumption during an 18 h cultivation of C. albicans hyphal cells. 
A. C. albicans yeast secretome map pH4-7 with spot labeling 
 
 
B. C.albicanshyphalsecretome map pH 4-7 with spot labeling 
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C. C.albicanshyphalsecretome map pH 7-11 with spot labeling 
 
Figure S-3 Spot labels of 2D gels 
 
Table S-1:  List of proteins identified in C. albicans SC5314 culture supernatants 
identified in at least 2 replicates with more than 2 peptides in one of them, ordered 
according to their predicted biological process. Secretomes of yeast form and hyphal 
form were analyzed separately. 
  Protein Description 
Identified peptides in biological replicates 
SP GPI Yeast Hyphae 
2D 
Gel 
Gel- 
free 
2D 
Gel 
Gel- 
free 
Cell wall associated proteins 
orf19.1597 ABG1 Vacuolar membrane protein     √ (6,6,7,7) Y N 
orf19.5007 ACT1 Actin     √ (8,10,13,11) N N 
orf19.3997 ADH1 Alcohol dehydrogenase     √ (10,16,13,14) N N 
orf19.2762 AHP1 Alkyl hydroperoxide reductase     √ (4,4,4,5) N N 
orf19.6214 ATC1  Cell wall acid trehalase   (4,3,3,3)   (3,4,6,3) N N 
orf19.6854 ATP1 ATP synthase alpha subunit       (11,9,13,12) N N 
orf19.4565 BGL2  Cell wall 1,3-beta-glucosyltransferase √ (14,14,14,15)   (11,11,14,10) Y N 
orf19.3014 BMH1  Sole 14-3-3 protein in C. albicans     √ (5,9,10,8) N N 
orf19.6229 CAT1 Catalase       (3,2,3,3) N N 
orf19.3575 CDC19 Pyruvate kinase at yeast cell surface     √ (13,16,12,14) N N 
orf19.1055 CDC3 Septin       (2,2,3,2) N N 
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  Protein Description 
Identified peptides in biological replicates 
SP GPI Yeast Hyphae 
2D 
Gel 
Gel- 
free 
2D 
Gel 
Gel- 
free 
orf19.4152 CEF3 Translation elongation factor 3       (13,10,19,10) N N 
orf19.7517 CHT1  Chitinase   (4,5,5,5)     Y Y 
orf19.3895 CHT2  GPI-linked chitinase   (10,10,10,11)   (10,11,12,11) Y Y 
orf19.7586 CHT3 Major chitinase   (7,7,7,8) √ (6,6,6,6) Y N 
orf19.2706 CRH11  GPI-anchored cell wall transglycosylase   (11,8,8,11)   (10,12,12,12) Y Y 
orf19.4477 CSH1 Aldo-keto reductase       (3,2,2,3) N N 
orf19.3010.1 ECM33  GPI-anchored cell wall protein   (8,8,8,8)   (6,9,9,7) Y Y 
orf19.4255 ECM331 GPI-anchored protein       (2,2,2,2) Y N 
orf19.5788 EFT2 Elongation factor 2     √ (26,34,34,32) N N 
orf19.3066 ENG1  Endo-1,3-beta-glucanase   (26,24,24,27)   (7,13,13,11) Y N 
orf19.395 ENO1  Enolase   (6,3,6,6) √ (19,20,21,20) N N 
orf19.2952 EXG2 GPI-anchored cell wall protein       (3,3,4) Y Y 
orf19.4618 FBA1  Fructose-bisphosphate aldolase     √ (14,17,17,17) N N 
orf19.251 GLX3  Glutathione-independent glyoxalase   (3,2,2,2) √ (11,12,10,11) N N 
orf19.7021 GPH1 Putative glycogen phosphorylase       (4,3,3,5) N N 
orf19.903 GPM1 Phosphoglycerate mutase     √ (8,11,10,10) N N 
orf19.2803 HEM13 Coproporphyrinogen III oxidase     √ (3,7,6,5) N N 
orf19.4980 HSP70  Putative hsp70 chaperone     √ (28,30,28,27) N N 
orf19.6515 HSP90  Essential chaperone   (2,3,3,4) √ (27,33,34,31) N N 
orf19.4975 HYR1 GPI-anchored hyphal cell wall protein       (3,7,6,6) Y Y 
orf19.5399 IFF11  Secreted protein   (2,3,3)     Y N 
orf19.7585 INO1 Inositol-1-phosphate synthase     √ (8,13,14,13) N N 
orf19.3590 IPP1  Putative inorganic pyrophosphatase     √ (10,11,12,12) N N 
orf19.4755 KEX2  Subtilisin-like protease    (5,5,8,7) √ (9,12,16,14) Y N 
orf19.290 KRE5 UDP-glucose:glycoprotein glucosyltransferase       (5,6,10,5) N N 
orf19.5645 MET15 O-acetylhomoserine O-acetylserine sulphydrylase     √ (11,14,12,12) N N 
orf19.2551 MET6  Cobalamin-independent methionine synthase   (4,6,6,5) √ (37,39,40,39) N N 
orf19.1665 MNT1  Alpha-1,2-mannosyl transferase   (5,4,6,5)   (8,12,17,11) N N 
orf19.1663 MNT2 Alpha-1,2-mannosyl transferase       (4,5,9,4) N N 
orf19.1779 MP65  Cell surface mannoprotein √ (16,17,18,18) √ (15,17,16,16) Y N 
orf19.1490 MSB2  Mucin family adhesin-like protein   (9,8,8,9)   (7,8,9,7) Y N 
orf19.2677 orf19.2677 Putative GPI transamidase component       (6,6,9,8) Y N 
orf19.6741 orf19.6741  Putative plasma membrane protein   (3,3,4,5)     N N 
orf19.2877 PDC11 Pyruvate decarboxylase     √ (10,17,16,16) N N 
orf19.4035 PGA4  GPI-anchored cell surface protein   (13,12,10,12)   (8,9,10,8) Y Y 
orf19.2451 PGA45  Putative GPI-anchored cell wall protein   (4,4,4,4)   (4,5,4,4) Y Y 
orf19.1911 PGA52  GPI-anchored cell surface protein of unknown function   (2,2,2,2)     Y Y 
orf19.3651 PGK1 Phosphoglycerate kinase      √ (21,27,25,25) N N 
orf19.3829 PHR1 Cell surface glycosidase       (18,21,22,21) Y Y 
orf19.6081 PHR2  Glycosidase   (7,8,7,8)     Y Y 
orf19.220 PIR1  1,3-beta-glucan-linked cell wall protein   (2,2,2,2)     N N 
orf19.1390 PMI1  Phosphomannose isomerase     √   N N 
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  Protein Description 
Identified peptides in biological replicates 
SP GPI Yeast Hyphae 
2D 
Gel 
Gel- 
free 
2D 
Gel 
Gel- 
free 
orf19.3765 RAX2 
Plasma membrane protein involved in 
establishment of bud sites and linear 
direction of hyphal growth 
      (6,10,12,8) Y N 
orf19.1327 RBT1 Cell wall protein with similarity to Hwp1     √ (7,7,12,9) Y Y 
orf19.5305 RHD3  GPI-anchored yeast-associated cell wall protein   (9,9,9,9)   (4,7,6,5) Y N 
orf19.2843 RHO1  Small GTPase of Rho family   (5,5,5,4)   (3,4,8,3) N N 
orf19.4660 RPS6A Ribosomal protein 6A       (3,3,5,5) N N 
orf19.657 SAM2 S-adenosylmethionine synthetase     √ (9,13,17,14) N N 
orf19.3893 SCW11  Cell wall protein √ (13,13,14,13) √ (10,11,10,11) Y N 
orf19.5032 SIM1  Adhesin-like protein √ (14,15,15,15)   (9,8,9,8) Y N 
orf19.2770.1 SOD1 Superoxide dismutase [Cu-Zn]     √ (3,5,4,3) N N 
orf19.2060 SOD5 Cu and Zn-containing superoxide dismutase       (5,6,6,6) Y Y 
orf19.6190 SRB1 Essential GDP-mannose pyrophosphorylase       (5,7,8,4) N N 
orf19.8667 SSA2 HSP70 family chaperonin √   √ (23,26,27,25) N N 
orf19.6367 SSB1 Hypothetical protein CaO19.6367     √ (16,17,15,18) N N 
orf19.1896 SSC1 Heat shock protein       (6,6,10,9) N N 
orf19.4772 SSU81  
Predicted adaptor protein involved in 
activation of MAP kinase-dependent 
signaling pathways 
  (3,3,3,3)     N N 
orf19.3642 SUN41  Cell wall glycosidase √ (12,8,9,12)   (9,11,10,11) Y N 
orf19.3414 SUR7  
Protein required for normal cell wall, 
plasma membrane, cytoskeletal 
organization, endocytosis 
  (3,3,3,3)     N N 
orf19.6814 TDH3  NAD-linked glyceraldehyde-3-phosphate dehydrogenase   (3,2,4,4) √ (15,18,19,17) N N 
orf19.1435 TEF1 Probable translation elongation factor EF-1 alpha     √   N N 
orf19.5112 TKL1 Transketolase I     √ (10,14,14,16) N N 
orf19.1690 TOS1  Protein similar to alpha agglutinin anchor subunit   (12,12,10,12) √ (14,14,14,14) Y N 
orf19.6745 TPI1  Triose-phosphate isomerase   (3,3,3,2) √ (8,10,8,9) N N 
orf19.7417 TSA1  TSA/alkyl hydroperoxide peroxidase C family protein     √ (7,7,8,8) N N 
orf19.1738 UGP1 UTP-glucose-1-phosphaturidyl transferase       (5,4,5,6) N N 
orf19.1671 UTR2  Putative GPI anchored cell wall glycosidase   (5,4,4,3)   (7,9,8,8) Y Y 
orf19.2990 XOG1 Exo-1,3-beta-glucanase √ (15,14,13,14) √ (12,12,14,13) Y N 
orf19.7676 XYL2  D-xylulose reductase     √ (3,8,4,5) N N 
orf19.6481 YPS7  
Putative aspartic-type endopeptidase 
with limited ability to degrade alpha 
pheromone 
  (6,5,6,5)   (4,7,6,3) Y N 
orf19.3618 YWP1  Secreted yeast wall protein √ (4,5,5,6)   (3,3,2,3) Y Y 
orf19.7218 RBE1 Pry family cell wall protein   (6,6,5,6)     Y N 
Secreted proteases, lipases and adhesins 
orf19.1339 CPY1 Carboxypeptidase Y     √ (13,15,15,15) Y N 
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  Protein Description 
Identified peptides in biological replicates 
SP GPI Yeast Hyphae 
2D 
Gel 
Gel- 
free 
2D 
Gel 
Gel- 
free 
orf19.1442 PLB4.5  Phospholipase B √ (24,24,23,24)   (10,17,17,13) Y Y 
orf19.1816 ALS3 Cell wall adhesin       (10,13,14,12) Y Y 
orf19.3591 APE3 Putative vacuolar aminopeptidase Y,     √ (19,21,23,20) Y N 
orf19.5197 APE2 Neutral arginine, alanine, leucine specific metallo-aminopeptidase     √ (13,14,14,14) N N 
orf19.5542 SAP6 secretory aspartyl proteinase SAP6p     √ (24,30,23,25) Y N 
orf19.5585 SAP5  Secreted aspartyl proteinase     √ (19,24,22,21) Y N 
orf19.5716 SAP4 Secreted aspartyl proteinase     √ (9,17,10,15) Y N 
orf19.5741 ALS1 Cell-surface adhesin       (5,4,4,4) Y Y 
orf19.690 PLB2 Putative phospholipase B       (2,7,5,4) Y N 
orf19.6928 SAP9  Secreted aspartyl protease   (4,3,4,4)   (4,6,7,5) Y Y 
orf19.709 PUP2  Alpha5 subunit of the 20S proteasome      √   N N 
orf19.756 SAP7  Pepstatin A-insensitive secreted aspartyl protease   (14,13,13,13)   (9,10,11,8) Y N 
orf19.3839 SAP10  Secreted aspartyl protease   (5,3,4,5)     Y Y 
orf19.3708 SAP2  Major secreted aspartyl proteinase   (4,4,3,4)     Y N 
orf19.6001 SAP3  Secreted aspartyl proteinase   (9,8,7,9)     Y N 
orf19.1097 ALS2  ALS family protein   (9,8,8,10)     Y N 
orf19.4555 ALS4  GPI-anchored adhesin   (3,3,2,2)     Y Y 
orf19.2133 LIP4 Secreted lipase √ (17,15,14,16)     Y N 
Carbohydrate metabolic process 
orf19.5113 ADH2 Alcohol dehydrogenase       (5,7,7,7) N N 
orf19.5013 AGM1 Phosphoacetylglucosamine mutase        (2,3,3,3) N N 
orf19.2334 BIG1  Endoplasmic reticulum (ER) protein   (2,2,2,2)     Y N 
orf19.4393 CIT1 Citrate synthase     √ (9,10,18,13) N N 
orf19.3670 GAL1 Galactokinase       (3,7,5,5) N N 
orf19.3672 GAL10 UDP-glucose 4-epimerase       (3,6,7,3) N N 
orf19.4899 GCA1 Extracellular/plasma membrane-associated glucoamylase       (4,13,9) Y N 
orf19.999 GCA2  Predicted extracellular glucoamylase   (5,2,4,5)   (5,13,10,9) Y N 
orf19.7394 GDA1  Golgi membrane GDPase   (3,3,3,3)   (4,6,10,5) N N 
orf19.1618 GFA1 Glucosamine-6-phosphate synthase       (3,2,5,4) N N 
orf19.734 GLK1 Putative glucokinase     √ (7,12,9,10) N N 
orf19.4317 GRE3 Putative D-xylose reductase     √ (4,6,4,5) N N 
orf19.6673 HEX1  Beta-N-acetylhexosaminidase/chitobiase   (7,6,5,8) √ (15,16,17,15) Y N 
orf19.6387 HSP104 Heat-shock protein       (8,6,9,10) N N 
orf19.822 HSP21  Small heat shock protein     √ (5,5,5,5) N N 
orf19.2154 HXK1 N-acetylglucosamine (GlcNAc) kinase       (3,5,4,3) N N 
orf19.542 HXK2 Likely hexokinase II     √   N N 
orf19.6844 ICL1 Isocitrate lyase       (5,3,3,3) N N 
orf19.4475 KTR4 Mannosyltransferase       (2,3,4,2) N N 
orf19.7080 LEU2 Isopropyl malate dehydrogenase     √ (6,10,10,9) N N 
orf19.7668 MAL2 Maltase     √ (15,18,21,18) N N 
orf19.7481 MDH1  Mitochondrial malate dehydrogenase      √ (7,4,6,7) N N 
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  Protein Description 
Identified peptides in biological replicates 
SP GPI Yeast Hyphae 
2D 
Gel 
Gel- 
free 
2D 
Gel 
Gel- 
free 
orf19.4602 MDH1-1 Predicted malate dehydrogenase precursor       (9,9,14,11) N N 
orf19.4833 MLS1 Malate synthase       (4,2,2,5) N N 
orf19.2347 MNN2  Alpha-1,2-mannosyltransferase   (2,4,3,3) √ (10,16,19,14) N N 
orf19.6692 MNN26 Putative alpha-1,2-mannosyltransferase       (8,10,19,9) N N 
orf19.1036 MNS1 Alpha-1,2-mannosidase √       N N 
orf19.2156 NAG1 Glucosamine-6-phosphate deaminase       (6,6,6,5) N N 
orf19.1946 orf19.1946 Hypothetical protein CaO19.1946     √ (4,5,6,6) N N 
orf19.3286 orf19.3286 Ortholog(s) have alpha-glucosidase activity       (5,4,6,3) Y N 
orf19.3982 orf19.3982 Maltase     √ (10,15,17,13) N N 
orf19.930 PET9 Mitochondrial ADP/ATP carrier protein involved in ATP biosynthesis       (7,6,9,7) N N 
orf19.3888 PGI1 Glucose-6-phosphate isomerase     √ (12,16,16,15) N N 
orf19.2841 PGM2 Ortholog of S. cerevisiae Pgm2     √ (9,13,14,12) N N 
orf19.2937 PMM1  Phosphomannomutase     √ (7,9,12,9) N N 
orf19.789 PYC2 Putative pyruvate carboxylase       (14,15,18,14) N N 
orf19.6029 ROT1  Similar to S. cerevisiae Rot1p   (2,2,2,2)     Y N 
orf19.974 ROT2 Alpha-glucosidase II, catalytic subunit     √ (10,12,14,12) Y N 
orf19.2941 SCW4  Putative cell wall protein   (2,2,2,2)     N N 
orf19.6640 TPS1 Trehalose-6-phosphate synthase       (2,3,3,3) N N 
orf19.2298 WBP1 Putative oligosaccharyltransferase subunit       (3,3,2) Y N 
Translation 
orf19.3426 ANB1 Translation initiation factor eIF-5A       (6,6,6,6) N N 
orf19.7382 CAM1 Putative translation elongation factor eEF1 gamma       (6,4,10,5) N N 
orf19.2560 CDC60 Cytosolic leucyl tRNA synthetase       (7,9,5,6) N N 
orf19.6702 DED81 Putative tRNA-Asn synthetase       (2,3,3,2) N N 
orf19.3838 EFB1 Translation elongation factor EF-1 beta       (3,3,4,3) N N 
orf19.437 GRS1 Putative tRNA-Gly synthetase       (9,10,15,9) N N 
orf19.2138 ILS1 Putative isoleucyl-tRNA synthetase       (4,7,9,6) N N 
orf19.6749 KRS1 Putative tRNA-Lys synthetase       (2,2,3,3) N N 
orf19.6220.3 MMD1 Mitochondrial protein       (3,3,4,2) N N 
orf19.2478.1 orf19.2478.1 60S ribosomal protein L7       (5,4,7,3) N N 
orf19.3341 orf19.3341 Putative tRNA-Arg synthetase       (2,3,5,3) N N 
orf19.3354 orf19.3354 Ortholog(s) have structural constituent of ribosome activity       (8,8,13,11) N N 
orf19.3572.3 orf19.3572.3 Ribosomal 60S subunit protein L31B       (3,2,3,3) N N 
orf19.4149.1 orf19.4149.1 Protein component of the small (40S) ribosomal subunit       (3,3,4,4) N N 
orf19.6220.4 orf19.6220.4 Ribosomal 60S subunit protein       (3,2,3,2) N N 
orf19.6415.1 orf19.6415.1 Ortholog(s) have structural constituent of ribosome activity       (2,3,2,3) N N 
orf19.6701 orf19.6701 Protein with similarity to amino acid-tRNA ligase       (3,3,6,4) N N 
orf19.2935 RPL10 Ribosomal protein L10       (4,4,4,4) N N 
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orf19.3465 RPL10A L10A ribosomal protein     √ (6,5,7,5) N N 
orf19.2232 RPL11 Ribosomal protein       (3,2,3,3) N N 
orf19.1635 RPL12 Likely cytosolic ribosomal protein L12     √ (5,4,7,6) N N 
orf19.2994 RPL13 Putative ribosomal subunit       (4,5,7,5) N N 
orf19.4931.1 RPL14 Ribosomal protein L14       (3,3,4,3) N N 
orf19.493 RPL15A Putative ribosomal protein       (4,3,5,5) N N 
orf19.5982 RPL18 Predicted ribosomal protein       (4,5,6,4) N N 
orf19.5904 RPL19A Ribosomal protein L19       (3,3,3,3) N N 
orf19.2309.2 RPL2 Putative 60S ribosomal protein L2       (4,4,7,4) N N 
orf19.4632 RPL20B Ribosomal protein L20       (2,2,3,3) N N 
orf19.687.1 RPL25 Putative rRNA-binding ribosomal protein component       (2,2,2) N N 
orf19.5225.2 RPL27A Ribosomal protein L27       (3,3,6,4) N N 
orf19.2864.1 RPL28 Putative ribosomal protein       (3,2,5,4) N N 
orf19.1601 RPL3 Ribosomal protein, large subunit       (6,5,10,7) N N 
orf19.3415.1 RPL32 Component of the large (60S) ribosomal subunit       (2,2,5,4) N N 
orf19.827.1 RPL39 Ribosomal protein L39       (2,3,3,3) N N 
orf19.7217 RPL4B Ribosomal protein 4B       (4,6,8,5) N N 
orf19.6541 RPL5 Ribosomal protein       (4,3,4,3) N N 
orf19.236 RPL9B  Ribosomal protein L9     √ (4,2,5,4) N N 
orf19.7015 RPP0 Putative ribosomal protein     √ (6,6,6,4) N N 
orf19.6403.1 RPP2A Acidic ribosomal protein       (3,3,3,2) Y N 
orf19.3002 RPS1 Putative ribosomal protein 10 of the 40S subunit       (6,6,12,6) N N 
orf19.6785 RPS12 Acidic ribosomal protein S12       (4,5,5,3) N N 
orf19.4193.1 RPS13 Putative ribosomal protein of the small subunit       (4,3,4,3) N N 
orf19.6265.1 RPS14B Putative ribosomal protein       (3,2,3,3) N N 
orf19.5927 RPS15 Putative ribosomal protein       (2,2,2,2) N N 
orf19.2994.1 RPS16A Putative 40S ribosomal subunit       (3,3,5,3) N N 
orf19.2329.1 RPS17B Ribosomal protein 17B       (4,3,5,4) N N 
orf19.7018 RPS18 Predicted ribosomal protein       (7,5,9,7) N N 
orf19.5996.1 RPS19A Putative ribosomal protein S19     √ (3,3,4,4) N N 
orf19.6375 RPS20 Putative ribosomal protein       (4,4,5,5) N N 
orf19.3334 RPS21 Protein component of the small (40S) subunit       (4,4,5,4) N N 
orf19.3325.3 RPS21B Ribosomal protein S21       (3,4,3,4) N N 
orf19.6265 RPS22A Predicted ribosomal protein       (3,3,3,3) N N 
orf19.6253 RPS23A Putative ribosomal protein       (3,3,2,2) N N 
orf19.5466 RPS24 Predicted ribosomal protein       (3,3,5,3) N N 
orf19.6286.2 RPS27 Putative ribosomal protein       (3,3,2,3) N N 
orf19.7048.1 RPS28B Putative ribosomal protein S28B       (3,3,3,3) N N 
orf19.6312 RPS3 Ribosomal protein S3     √ (8,7,13,9) N N 
orf19.4336 RPS5 Ribosomal protein S5       (6,6,7,5) N N 
orf19.1700 RPS7A Ribosomal protein S7       (7,8,8,8) N N 
orf19.6873 RPS8A Small 40S ribosomal subunit protein       (4,4,6,5) N N 
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orf19.838.1 RPS9B Predicted ribosomal protein       (5,4,6,6) N N 
orf19.269 SES1 Seryl-tRNA synthetase       (3,3,3,2) N N 
orf19.1280 SUI1 Putative translation initiation factor       (2,2,2,2) N N 
orf19.382 TEF2  Translation elongation factor 1-alpha     √ (15,16,18,17) N N 
orf19.3324 TIF Translation initiation factor     √ (12,18,18,16) N N 
orf19.3087 UBI3  Fusion of ubiquitin with the S34 protein of the small ribosomal subuni   (5,4,3,5)   (7,9,9,8) N N 
orf19.6975 YST1 Ribosome-associated protein      √ (6,5,6,5) N N 
Response to stimuli 
orf19.1891 APR1 Vacuolar aspartic proteinase       (10,12,11,11) Y N 
orf19.3171 ACH1 Acetyl-coA hydrolase     √ (5,5,8,8) N N 
orf19.7484 ADE1 Phosphoribosylaminoimadazole succinocarboxamide synthetase       (3,3,3,3) N N 
orf19.3870 ADE13 Adenylosuccinate lyase       (4,5,7,5) N N 
orf19.5591 ADO1 Adenosine kinase     √ (7,9,9,9) N N 
orf19.7602 AHA1 Putative Hsp90p co-chaperone       (4,3,4,4) N N 
orf19.5964 ARF2  Putative ADP-ribosylation factor   (3,3,4,4) √ (5,8,8,8) N N 
orf19.6906 ASC1  40S ribosomal subunit similar to G-beta subunits   (3,3,7,5) √ (9,10,8,12) N N 
orf19.5641 CAR2 Ornithine aminotransferase       (3,3,4,3) N N 
orf19.2340 CDC48 Putative microsomal ATPase  √     (8,4,5,9) N N 
orf19.2157 DAC1 N-acetylglucosamine-6-phosphate (GlcNAcP) deacetylase       (3,5,4,3) N N 
orf19.4688 DAG7  Secretory protein   (6,5,5,6)   (4,4,4,4) Y N 
orf19.2613 ECM4 Cytoplasmic glutathione S-transferase       (4,5,3,4) N N 
orf19.7312 ERG13 3-hydroxy-3-methylglutaryl coenzyme A synthase       (3,3,5,3) N N 
orf19.979 FAS1 Beta subunit of fatty-acid synthase       (21,21,26,15) N N 
orf19.4215 FET34 Multicopper ferroxidase       (3,3,2,2) Y N 
orf19.1153 GAD1 Putative glutamate decarboxylase       (9,5,3,8) N N 
orf19.5024 GND1 6-phosphogluconate dehydrogenase     √ (19,25,28,23) N N 
orf19.86 GPX1 Potential glutathione peroxidase/redox transducer     √   N N 
orf19.2727 GRX3 Putative glutaredoxin       (2,3,2,2) N N 
orf19.717 HSP60 Heat shock protein       (10,9,11,12) N N 
orf19.2013 KAR2  Similar to Hsp70 family chaperones   (20,17,16,20) √ (34,36,40,35) N N 
orf19.5830 LHS1  Protein similar to S. cerevisiae Hsp70p   (5,5,6,7)   (13,16,23,17) N N 
orf19.3507 MCR1 NADH-cytochrome-b5 reductase       (8,6,5,5) N N 
orf19.2435 MSI3 Essential HSP70 family protein       (11,13,18,15) N N 
orf19.2028 MXR1 Putative methionine sulfoxide reductase       (3,3,3,2) N N 
orf19.2304  orf19.2304 Protein similar to S. cerevisiae Gvp36p  √       N N 
orf19.3438 orf19.3438 Ortholog(s) have chaperone binding activity       (2,2,4,3) Y N 
orf19.4150 orf19.4150 Putative glutaredoxin       (2,2,3,2) Y N 
orf19.5322 orf19.5322  Phosphatidylinositol-3-phosphate binding activity   (5,3,4,4)     Y N 
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orf19.7578 orf19.7578  Ortholog(s) have oligosaccharide binding activity   (3,2,3,3)   (4,5,5,4) Y N 
orf19.3727 PHO112  Putative constitutive acid phosphatase   (6,11,7,9)     N N 
orf19.5383 PMA1 Plasma membrane H(+)-ATPase       (8,8,9,8) N N 
orf19.12086 POL30  Similar to proliferating cell nuclear antigen (PCNA)     √   N N 
orf19.5180 PRX1 Thioredoxin peroxidase     √ (9,12,11,11) N N 
orf19.3702 RBP1 Peptidyl-prolyl cis-trans isomerase     √ (2,3,3,3) N N 
orf19.6202 RBT4  Pry family protein   (5,5,4,5) √ (7,10,9,8) Y N 
orf19.5968 RDI1 Putative rho GDP dissociation inhibitor     √ (8,10,11,9) N N 
orf19.6085 RPL16 Ribosomal protein L16     √ (3,2,6,2) N N 
orf19.4490 RPL17B Ribosomal protein L17       (3,2,3,2) N N 
orf19.3003.1 RPL6 Ortholog of S. cerevisiae ribosomal subunit, Rpl6B       (4,4,5,4) N N 
orf19.5823 SGT2 Putative small tetratricopeptide repeat (TPR)-containing protein       (4,5,5,4) N N 
orf19.670 SMT3 SUMO, small ubiquitin-like protein       (3,4,3,3) N N 
orf19.3340 SOD2 Mitochondrial Mn-containing superoxide dismutase       (3,2,2,2) N N 
orf19.1453 SPT5 Transcription elongation factor     √   N N 
orf19.5647 SUB2 Putative TREX complex component with a predicted role in nuclear mRNA export       (3,3,3,3) N N 
orf19.6068 SVF1 Putative survival factor       (2,2,3,3) N N 
orf19.3268 TMA19 Hypothetical protein CaO19.3268     √ (4,5,4,5) N N 
orf19.4290 TRR1 Thioredoxin reductase     √ (3,3,3,3) N N 
orf19.6059 TTR1 Putative glutaredoxin       (3,3,3,3) N N 
orf19.7308 TUB1 Alpha-tubulin       (5,6,7,5) N N 
orf19.6034 TUB2 Beta-tubulin       (5,4,5,4) N N 
orf19.6109 TUP1 Transcriptional corepressor       (3,3,3,4) N N 
orf19.4311 YNK1 Nucleoside diphosphate kinase (NDP kinase)     √ (6,7,7,7) N N 
orf19.4754 ZWF1 Glucose-6-phosphate dehydrogenase     √ (10,10,9,12) N N 
orf19.7196 PRB12 Hypothetical protein CaO19.7196     √   Y N 
vesicle-mediated transport 
orf19.953.1 COF1  Putative cofilin     √ (7,7,7,6) N N 
orf19.6293 EMP24 COPII-coated vesicle component       (3,2,3,2) Y N 
orf19.731 EMP46  Protein similar to S. cerevisiae Emp46   (3,3,4,4) √ (11,10,13,11) Y N 
orf19.7409 ERV25  Component of COPII-coated vesicles   (4,3,3,4)   (2,3,2,3) Y N 
orf19.3149 LSP1 Eisosome component with a predicted role in endocytosis       (4,4,5,4) N N 
orf19.2416.1 MLC1 Microtubule-dependent localized protein       (4,5,5,4) N N 
orf19.2168.3 orf19.2168.3  Ortholog(s) have role in cellular protein localization   (2,2,2,2)     N N 
orf19.3767 PEP1  Type I transmembrane sorting receptor for multiple vacuolar hydrolases   (5,6,5,6)   (7,8,15,5) N N 
orf19.4236 RET2 Delta subunit of the coatomer complex (COPI)       (3,2,3) N N 
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orf19.3462 SAR1 Functional homolog of S. cerevisiae Sar1       (2,4,6,3) N N 
orf19.1680 TFP1 Subunit of vacuolar H+-ATPase       (4,3,2,3) N N 
orf19.7611 TRX1  Thioredoxin   (4,4,4,4)   (4,5,4,4) N N 
orf19.2974 YKT6 Putative protein of the vacuolar SNARE complex       (5,8,8,5) N N 
orf19.3052 YPT1 Functional homolog of S. cerevisiae Ypt1p       (3,3,2,3) N N 
orf19.2622 YPT31  Protein required for resistance to toxic ergosterol analog   (3,3,2,3)   (5,7,5,5) N N 
orf19.7261 GDI1 Hypothetical protein CaO19.7261     √ (3,6,9,5) N N 
Protein folding 
orf19.6472 CYP1  Peptidyl-prolyl cis-trans isomerase   (3,2,2,3)   (6,9,8,8) N N 
orf19.7421 CYP5 Putative peptidyl-prolyl cis-trans isomerase   (8,8,7,8) √ (12,13,13,13) Y N 
orf19.4871 ERO1  Ortholog of S. cerevisiae Ero1   (3,3,3,3)   (4,4,5,2) Y N 
orf19.3396 HCH1 Ortholog of S. cerevisiae Hch1       (3,4,3,2) N N 
orf19.4952.1 orf19.4952.1 Ortholog(s) have FK506 binding, Hsp70 protein binding √ (3,3,3,3) √ (4,5,5,4) Y N 
orf19.7215.3 orf19.7215.3 Chaperone binding, unfolded protein binding activity       (4,5,5,4) N N 
orf19.5130 PDI1  Putative protein disulfide-isomerase   (13,11,13,13) √ (28,29,30,29) Y N 
orf19.3192 STI1 Protein that interacts with Cdc37 and Crk1 in two-hybrid       (9,8,8,9) N N 
Regulation of biological process 
orf19.2699 ABP1 Ortholog of S. cerevisiae Abp1       (5,6,7,7) N N 
orf19.6385 ACO1 Aconitase     √ (7,10,15,11) N N 
orf19.1282 CKS1 
Ortholog(s) have histone binding, protein 
complex binding, protein 
homodimerization activity 
      (2,2,3,3) N N 
orf19.7654 CPR6 Putative peptidyl-prolyl cis-trans isomerase       (4,4,4,4) N N 
orf19.5949 FAS2 Alpha subunit of fatty-acid synthase       (12,10,18,9) N N 
orf19.5493 GSP1 Small RAN G-protein     √ (3,5,5,5) N N 
orf19.6127 LPD1 Putative dihydrolipoamide dehydrogenase     √ (7,3,6,5) N N 
orf19.3294 MBF1 Putative transcriptional coactivator       (3,4,4,2) N N 
orf19.13277 MBP1  
Putative component of the MBF 
transcription complex involved in G1/S 
cell-cycle progression 
    √   N N 
orf19.1448.1 orf19.1448.1 Ortholog(s) have plus-end-directed microtubule motor activity       (0,2,2,2) N N 
orf19.2489 orf19.2489 Putative karyopherin beta       (2,4,6,3) N N 
orf19.2757 orf19.2757 Has domain(s) with predicted role in cell redox homeostasis       (6,8,11,8) Y N 
orf19.2769 orf19.2769  Putative protease B inhibitor   (3,3,3,3)   (3,3,3,4) N N 
orf19.3037 orf19.3037 Putative poly(A)-binding protein       (8,9,5,8) N N 
orf19.5201.1 orf19.5201.1 Has domain(s) with predicted enzyme inhibitor activity       (3,2,3,2) N N 
orf19.5076 PFY1 Profilin       (4,5,5,4) N N 
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orf19.5956 PIN3 Putative SH3-domain-containing protein       (3,3,3,2) Y N 
orf19.1042 POR1 Mitochondrial outer membrane porin       (3,4,7,6) N N 
orf19.2242 PRB1 Endoprotease B       (9,11,12,11) N N 
orf19.2241 PST1 Putative 1,4-benzoquinone reductase       (2,2,2) N N 
orf19.5285 PST3  Putative flavodoxin     √ (4,6,6,4) N N 
orf19.1649 RNA1 Putative GTPase-activating protein       (3,2,3,2) N N 
orf19.5544 SAC6 Fimbrin       (4,3,3,3) N N 
orf19.1974 TFS1  Putative carboxypeptidase y inhibitor   (3,2,3) √ (4,3,3,3) N N 
orf19.754 YBN5 P-loop ATPase with similarity to human OLA1 and bacterial YchF       (2,5,5,3) N N 
orf19.7477 YRB1  Functional homolog of S. cerevisiae Yrb1p     √   N N 
orf19.6472 CYP1  Peptidyl-prolyl cis-trans isomerase   (3,2,2,3)   (6,9,8,8) N N 
orf19.5130 PDI1  Putative protein disulfide-isomerase   (13,11,13,13) √ (28,29,30,29) Y N 
lipid metabolic process 
orf19.1591 ERG10 Acetyl-CoA acetyltransferase       (5,10,8,8) N N 
orf19.4491 ERG20 Putative farnesyl pyrophosphate synthetase       (3,5,4,3) N N 
orf19.2775 IDI1 Ortholog(s) have isopentenyl-diphosphate delta-isomerase activity       (4,8,6,4) N N 
orf19.6105 MVD Mevalonate diphosphate decarboxylase       (5,7,5,5) N N 
orf19.100 orf19.100 Alpha/beta hydrolase and lipase domain protein       (4,4,5,3) Y N 
orf19.3911 SAH1 S-adenosyl-L-homocysteine hydrolase       (10,12,17,13) N N 
cellular respiration 
orf19.1471 COX4 Putative cytochrome c oxidase subunit IV       (2,5,3,3) N N 
orf19.1770 CYC1 Cytochrome c       (4,6,6,5) N N 
orf19.6724 FUM12 Putative fumarate hydratase       (3,3,7,5) N N 
orf19.4826 IDH1 Putative mitochondrial NAD-isocitrate dehydrogenase subunit 1       (6,2,7,5) N N 
orf19.5791 IDH2 Putative mitochondrial NAD-isocitrate dehydrogenase subunit     √ (7,4,6,6) N N 
transport 
orf19.7043.1 ACB1 Protein similar to a region of acyl-coenzyme-A-binding protein       (2,4,4,2) N N 
orf19.5653 ATP2 F1 beta subunit of F1F0 ATPase complex     √ (12,10,15,13) N N 
orf19.5858 EGD2  Nascent polypeptide associated complex protein alpha subunit     √ (2,3,2,2) N N 
orf19.2322.3 ERP5 Protein involved in ER to Golgi transport       (3,5,3,3) Y N 
orf19.6327 HET1  Putative sphingolipid transfer protein   (4,3,3,4)   (5,7,6,7) N N 
orf19.4879.2 NTF2 Putative nuclear envelope protein       (3,3,2,3) N N 
orf19.6570 NUP  Nucleoside permease   (2,2,3,3)     Y N 
orf19.3219 orf19.3219 Ortholog of S. cerevisiae Sia1       (5,5,5,3) N N 
orf19.3226 orf19.3226  Ortholog(s) have role in intracellular sterol transport and extracellular region   (4,3,4,4)   (4,4,5,4) Y N 
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orf19.590 orf19.590 Putative thiamine biosynthesis enzyme       (3,4,4,3) N N 
orf19.6403 orf19.6403  Ortholog(s) have adenyl-nucleotide exchange factor activity      √ (8,9,11,10) Y N 
orf19.7438 UBA1 Ubiquitin-activating enzyme       (4,8,9,6) N N 
organelle organization 
orf19.1064 ACS2 Acetyl-CoA synthetase     √ (11,14,16,14) N N 
orf19.88 ILV5 Ketol-acid reductoisomerase     √ (4,5,8,6) N N 
orf19.3799 orf19.3799 
Ortholog(s) have role in endoplasmic 
reticulum tubular network maintenance, 
nuclear pore complex assembly and Golgi 
apparatus, cortical endoplasmic reticulum 
      (3,4,4,2) N N 
orf19.7310 orf19.7310  
Protein with a role in directing meiotic 
recombination events to homologous 
chromatids 
  (3,2,4,3)     Y N 
orf19.2769 orf19.2769  Putative protease B inhibitor   (3,3,3,3)   (3,3,3,4) N N 
orf19.3087 UBI3  Fusion of ubiquitin with the S34 protein of the small ribosomal subuni   (5,4,3,5)   (7,9,9,8) N N 
unknown function 
orf19.5063 COI1 Secreted protein √ (9,9,9,9)   (9,9,11,10) Y N 
orf19.1239 orf19.1239  Secreted protein   (5,6,7,5)   (5,0,5,4) Y N 
orf19.1350 orf19.1350 Protein with a thioredoxin domain       (2,2,3,2) N N 
orf19.1383  orf19.1383 Protein of unknown function     √   N N 
orf19.1533 orf19.1533 Possible vacuolar protein       (2,2,2,3) Y N 
orf19.1766 orf19.1766  Secreted protein; fluconazole-induced   (4,4,4,4)     Y N 
orf19.2036 orf19.2036 Predicted dihydrodiol dehydrogenase       (4,4,5,4) N N 
orf19.2125 orf19.2125 Protein of unknown function       (6,5,5,5) N N 
orf19.2452 orf19.2452 Protein of unknown function       (3,3,5,3) Y N 
orf19.2460 orf19.2460  Protein of unknown function   (2,3,3,3)   (4,6,7,4) Y N 
orf19.2645  orf19.2645        √   N N 
orf19.3004 orf19.3004 Ortholog(s) have fungal-type vacuole localization       (4,4,5,4) Y N 
orf19.3053 orf19.3053 Protein of unknown function     √ (4,5,4,4) N N 
orf19.3173 orf19.3173        √ (8,10,11,10) Y N 
orf19.3475 orf19.3475 Described as a Gag-related protein       (4,4,4,3) N N 
orf19.3499 orf19.3499 Secreted potein       (4,6,4,4) Y N 
orf19.3910 orf19.3910 Has domain(s) with predicted RNA binding, ribonuclease T2 activity       (7,11,11,10) Y N 
orf19.3932 orf19.3932 Predicted RNA binding protein       (3,2,3,3) N N 
orf19.4376 orf19.4376 Protein of unknown function √       N N 
orf19.4609 orf19.4609 Putative dienelactone hydrolase       (4,7,4,7) N N 
orf19.4787  orf19.4787 Ortholog(s) have cytoplasm, nucleus localization √       N N 
orf19.5925 orf19.5925      (2,3,4,3)   (3,4,4,4) N N 
orf19.6119 orf19.6119  Protein of unknown function   (8,7,7,7)     N N 
orf19.6200 orf19.6200 Pry family pathogenesis-related protein       (3,5,4,4) Y N 
orf19.6487 orf19.6487      (3,3,3,3)     Y N 
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  Protein Description 
Identified peptides in biological replicates 
SP GPI Yeast Hyphae 
2D 
Gel 
Gel- 
free 
2D 
Gel 
Gel- 
free 
orf19.6553 orf19.6553 Hypothetical protein CaO19.6553     √ (14,14,16,14) Y N 
orf19.6809 orf19.6809 Putative phosphomutase-like protein       (3,4,6,3) N N 
orf19.6867 orf19.6867 Protein with a predicted cytochrome b5-like heme/steroid binding domain       (2,3,2,2) N N 
orf19.7297 orf19.7297 Putative cystathionine gamma-synthase       (4,4,6,5) N N 
orf19.2619 PHO113  Putative constitutive acid phosphatase   (6,9,8,9)     N N 
orf19.2681 RBT7  Protein with similarity to RNase T2 enzymes   (2,2,2,3)     Y N 
orf19.7350 RCT1  Fluconazole-induced protein      √ (7,8,9,9) N N 
orf19.3789 RPL24A Predicted ribosomal protein       (3,2,4,2) N N 
orf19.6663 RPS25B Ribosomal protein       (2,2,3,3) N N 
orf19.5078 OFR1 Protein of unknown function       (3,4,5,4) N N 
Others 
orf19.3554 AAT1 Aspartate aminotransferase       (4,3,6,5) N N 
orf19.6287 AAT2 Potential aspartate aminotransferase     √ (8,8,8,8) N N 
orf19.492 ADE17 5-Aminoimidazole-4-carboxamide ribotide transformylase     √ (10,9,9,8) N N 
orf19.3391 ADK1 Putative adenylate kinase       (3,3,4,2) N N 
orf19.5806 ALD5 NAD-aldehyde dehydrogenase     √ (12,10,16,14) N N 
orf19.7469 ARG1 Argininosuccinate synthase     √ (6,8,8,6) N N 
orf19.1986 ARO2 Putative chorismate synthase     √   N N 
orf19.1517 ARO3 3-deoxy-D-arabinoheptulosonate-7-phosphate synthase       (4,4,4,5) N N 
orf19.2098 ARO8 Aromatic transaminase aromatic alcohol biosynthesis       (8,4,8,4) N N 
orf19.5292 AXL2 Ortholog of S. cerevisiae Axl2       (4,3,3,3) N N 
orf19.6994 BAT22  Putative branched chain amino acid aminotransferase     √ (4,6,7,4) N N 
orf19.6402 CYS3 Cystathionine gamma-lyase       (4,6,5,5) N N 
orf19.3322 DUT1   dUTP pyrophosphatase     √   N N 
orf19.3374 ECE1 Hypha-specific protein       (16,17,21,15) N N 
orf19.299 ECM14 Ortholog(s) have endoplasmic reticulum, fungal-type vacuole localization     √ (24,25,26,25) Y N 
orf19.7600 FDH3 Glutathione-dependent formaldehyde dehydrogenase       (4,7,6,5) N N 
orf19.4212 FET99  Multicopper oxidase family protein   (4,4,5,4)     Y N 
orf19.2192 GDH2 Putative NAD-specific glutamate dehydrogenase       (3,3,3,5) N N 
orf19.4716 GDH3  NADP-glutamate dehydrogenase     √ (13,16,13,14) N N 
orf19.6058 GLO1 Putative monomeric glyoxalase I       (3,3,3,3) N N 
orf19.4309 GRP2 Methylglyoxal reductase     √ (8,8,8,10) N N 
orf19.1078 HBR2  Putative alanine glyoxylate aminotransferase     √   N N 
orf19.4026 HIS1 ATP phosphoribosyl transferase       (3,2,3,2) N N 
orf19.1559 HOM2 Aspartate-semialdehyde dehydrogenase       (5,7,7,6) N N 
orf19.2951 HOM6 hypothetical protein CaO19.2951     √ (4,5,6,5) N N 
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2D 
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Gel- 
free 
2D 
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Gel- 
free 
orf19.5832 HPT1 Putative hypoxanthine-guanine phosphoribosyltransferase       (3,2,3,2) N N 
orf19.5211 IDP1 Putative isocitrate dehydrogenase       (6,5,4,5) N N 
orf19.3733 IDP2  Isocitrate dehydrogenase     √ (9,13,13,13) N N 
orf19.2396 IFR2  Zinc-binding dehydrogenase     √ (2,3,2,3) N N 
orf19.6561 LAT1 
Putative dihydrolipoamide 
acetyltransferase component (E2) of 
pyruvate dehydrogenase complex 
      (3,2,5,3) N N 
orf19.7498 LEU1 3-isopropylmalate dehydratase       (2,3,4,3) N N 
orf19.3358 LSC1 Putative succinate-CoA ligase subunit       (3,3,7,4) N N 
orf19.1860 LSC2 Putative succinate-CoA ligase beta subunit       (3,3,4,3) N N 
orf19.1789.1 LYS1 Saccharopine dehydrogenase (biosynthetic)       (6,8,8,9) N N 
orf19.2525 LYS12 Homoisocitrate dehydrogenase       (3,3,3,2) N N 
orf19.4506 LYS22 Putative homocitrate synthase       (5,3,3,5) N N 
orf19.7448 LYS9  Saccharopine dehydrogenase      √ (7,6,7,5) N N 
orf19.2364 MIS11 Predicted mitochondrial C1-tetrahydrofolate synthase precursor       (6,5,12,9) N N 
orf19.1366  orf19.1366        √   N N 
orf19.1862 orf19.1862 Possible stress protein       (3,4,3,3) N N 
orf19.2269 orf19.2269 Putative 3-phosphoserine phosphatase       (3,4,5,3) N N 
orf19.2516 orf19.2516  Has domain(s) with predicted role in cell redox homeostasis   (4,3,3,3)     Y N 
orf19.3915 orf19.3915 Putative metallodipeptidase       (4,3,6,7) N N 
orf19.5206 orf19.5206 Putative chaperone protein √       N N 
orf19.5342 orf19.5342 Ortholog(s) have cytosol, extracellular region etw       (16,18,18,19) Y N 
orf19.540 orf19.540 Has domain(s) with predicted palmitoyl-(protein) hydrolase activity       (4,3,4,2) N N 
orf19.5773 orf19.5773 Hypothetical protein CaO19.5773     √ (6,5,5,4) N N 
orf19.6596 orf19.6596  Putative esterase      √   N N 
orf19.6630 orf19.6630 Role in ER-associated ubiquitin-dependent protein catabolic process       (5,5,6,6) Y N 
orf19.6732 orf19.6732 Ortholog(s) have cytosol, nucleus localization √       N N 
orf19.6882 OSM1 Putative flavoprotein subunit of fumarate reductase       (2,6,4,4) Y N 
orf19.5294 PDB1 Putative pyruvate dehydrogenase       (3,2,3,3) N N 
orf19.984 PHO8 Putative repressible vacuolar alkaline phosphatase       (3,2,4,3) Y N 
orf19.317 PNP1  Purine nucleoside phosphorylase     √   N N 
orf19.4135 PRC2  Putative carboxypeptidase   (4,4,2,2)   (11,13,12,12) Y N 
orf19.2474 PRC3  Putative carboxypeptidase Y precursor       (12,13,12,13) Y N 
orf19.434 PRD1 Putative proteinase       (5,8,11,6) N N 
orf19.7178 PRE5  Alpha6 subunit of the 20S proteasome     √   N N 
orf19.4024 RIB5 Putative riboflavin synthase       (3,3,2,2) N N 
orf19.6002 RPL8B Predicted ribosomal protein       (6,4,11,7) N N 
orf19.5484 SER1 Putative 3-phosphoserine aminotransferase     √ (5,4,3,5) N N 
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free 
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orf19.5750 SHM2 Cytoplasmic serine hydroxymethyltransferase       (6,6,9,7) N N 
orf19.2947 SNZ1 Hypothetical protein CaO19.2947     √ (5,8,5,5) N N 
orf19.704 SOL3 Putative 6-phosphogluconolactonase       (4,5,6,6) N N 
orf19.4371 TAL1 Transaldolase     √ (17,20,20,18) N N 
orf19.4233 THR4 Putative threonine synthase     √ (4,8,9,8) N N 
orf19.2555 URA5 Putative orotate phosphoribosyltransferase     √ (3,3,2,4) N N 
orf19.6274 PBR1 hypothetical protein CaO19.6274     √ (3,6,4,4) N N 
 
Table S-2 Quantative analysis via TMT labeling 
 "upregulated" proteins in C. albicans yeast cells  
Ratio 
Y/H per 
100µg 
protein 
Ratio Y/H 
normalized 
to biomass 
Accession Gene  Description 
22.77  8.54  orf19.3618 YWP1 Secreted yeast wall protein 
6.43  2.41  orf19.4688 DAG7  Secretory protein 
5.86  2.20  orf19.4555 ALS4 GPI-anchored adhesin 
5.81  2.18  orf19.1442 PLB4.5 Phospholipase B 
5.63  2.11  orf19.7218 RBE1  Pry family cell wall protein 
5.49  2.06  orf19.220 PIR1  1,3-beta-glucan-linked cell wall protein 
5.40  2.03  orf19.7517 CHT1  Chitinase 
 
"upregulated" proteins in C. albicans hyphal cells 
Ratio 
Y/H per 
100µg 
protein 
Ratio Y/H 
normalized 
to biomass 
Ratio H/Y 
normalized 
to biomass 
Accession Gene  Description 
0.45  0.17  5.95  orf19.3591 APE3  Putative vacuolar aminopeptidase Y 
0.45  0.17  5.87  orf19.1327 RBT1  Cell wall protein with similarity to Hwp1 
0.46  0.17  5.82  orf19.1816 ALS3 Cell wall adhesin 
0.47  0.18  5.62  orf19.7350 RCT1 Fluconazole-induced protein 
0.49  0.18  5.43  orf19.1597 ABG1  Vacuolar membrane protein 
0.52  0.20  5.12  orf19.6553 orf19.6553  
Membrane-localized protein of  
unknown function 
0.54  0.20  4.90  orf19.7421 CYP5 Putative peptidyl-prolyl cis-trans isomerase 
0.55  0.20  4.89  orf19.4311 YNK1 Nucleoside diphosphate kinase (NDP kinase) 
0.55  0.21  4.87  orf19.2309.2 RPL2  Putative 60S ribosomal protein L2 
0.56  0.21  4.78  orf19.5130 PDI1  Putative protein disulfide-isomerase 
0.57  0.21  4.69  orf19.1770 CYC1 Cytochrome c 
0.57  0.21  4.67  orf19.7571 UBC4 Ortholog(s) have ubiquitin binding activity 
0.58  0.22  4.62  orf19.6472 CYP1  Peptidyl-prolyl cis-trans isomerase 
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Ratio 
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100µg 
protein 
Ratio Y/H 
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Ratio H/Y 
normalized 
to biomass 
Accession Gene  Description 
0.58  0.22  4.60  orf19.6085 RPL16A  Ribosomal protein 
0.59  0.22  4.50  orf19.6058 GLO1  Putative monomeric glyoxalase I 
0.59  0.22  4.49  orf19.5180 PRX1  Thioredoxin peroxidase 
0.59  0.22  4.48  orf19.5542 SAP6  Secreted aspartyl protease 
0.60  0.23  4.41  orf19.299 ECM14  ER, fungal-type vacuole localization 
0.61  0.23  4.39  orf19.5585 SAP5  Secreted aspartyl proteinase 
0.61  0.23  4.39  orf19.3268 TMA19 Cell wall protein 
0.61  0.23  4.34  orf19.3004 orf19.3004 Fungal-type vacuole localization 
0.61  0.23  4.34  orf19.7477 YRB1  Functional homolog of S. cerevisiae Yrb1p 
0.63  0.24  4.24  orf19.6274 PBR1 Protein of unknown function 
0.63  0.24  4.22  orf19.6403 orf19.6403  Adenyl-nucleotide exchange factor activity 
0.65  0.25  4.07  orf19.3475 orf19.3475  A Gag-related protein 
0.67  0.25  4.00  orf19.4371 TAL1 Transaldolase 
0.67  0.25  3.99  orf19.6814 TDH3 
NAD-linked glyceraldehyde-3-phosphate 
dehydrogenase 
0.67  0.25  3.95  orf19.731 EMP46 Protein similar to S. cerevisiae Emp46 
0.68  0.25  3.94  orf19.3087 UBI3 
Fusion of ubiquitin with the S34 protein  
of the small ribosomal subunit 
0.69  0.26  3.88  orf19.4618 FBA1 Fructose-bisphosphate aldolase 
0.69  0.26  3.87  orf19.2757 orf19.2757 
Has domain(s) with predicted role in cell 
 redox homeostasis 
0.69  0.26  3.84  orf19.1745 orf19.1745 Protein of unknown function 
0.71  0.27  3.75  orf19.7196 orf19.7196 Putative vacuolar protease 
0.73  0.27  3.67  orf19.382 TEF2 Translation elongation factor 1-alpha 
0.73  0.27  3.65  orf19.3426 ANB1 Translation initiation factor eIF-5A 
0.74  0.28  3.59  orf19.395 ENO1 Enolase 
0.75  0.28  3.57  orf19.3002 RPS1 
Putative ribosomal protein 10 of the 40S  
subunit 
0.75  0.28  3.55  orf19.5342 orf19.5342 
Cytosol, extracellular region, fungal-type  
vacuole, nucleus localization 
0.75  0.28  3.55  orf19.6673 HEX1 Beta-N-acetylhexosaminidase/chitobiase 
0.75  0.28  3.53  orf19.2013 KAR2 Similar to Hsp70 family chaperones 
0.76  0.28  3.51  orf19.7668 MAL2 Alpha-glucosidase 
0.76  0.29  3.50  orf19.5806 ALD5 NAD-aldehyde dehydrogenase 
0.77  0.29  3.45  orf19.903 GPM1 Phosphoglycerate mutase 
0.78  0.29  3.44  orf19.3173 orf19.3173 Golgi apparatus, ER, localization 
0.78  0.29  3.42  orf19.2994 RPL13 Putative ribosomal subunit 
0.78  0.29  3.42  orf19.3888 PGI1 Glucose-6-phosphate isomerase 
0.79  0.29  3.39  orf19.3910 orf19.3910 
Predicted RNA binding, ribonuclease  
T2 activity 
0.79  0.30  3.38  orf19.1339 CPY1 Carboxypeptidase Y 
0.79  0.30  3.37  orf19.1690 TOS1 
Protein similar to alpha agglutinin anchor  
subunit 
0.80  0.30  3.35  orf19.2877 PDC11 Pyruvate decarboxylase 
0.80  0.30  3.31  orf19.5024 GND1 6-phosphogluconate dehydrogenase 
0.81  0.30  3.31  orf19.2551 MET6 
cobalamin-independent methionine  
synthase 
0.81  0.30  3.31  orf19.2651 CAM1-1 Putative translation elongation factor 
0.81  0.30  3.31  orf19.6253 RPS23A Putative ribosomal protein 
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0.81  0.30  3.30  orf19.5982 RPL18 Predicted ribosomal protein 
0.81  0.30  3.29  orf19.4660 RPS6A Ribosomal protein 6A 
0.81  0.30  3.29  orf19.838.1 RPS9B Predicted ribosomal protein 
0.82  0.31  3.27  orf19.5788 EFT2 Elongation Factor 2 (eEF2) 
0.82  0.31  3.26  orf19.3982 orf19.3982 Maltase 
0.82  0.31  3.26  orf19.3575 CDC19 Pyruvate kinase at yeast cell surface 
0.83  0.31  3.22  orf19.3651 PGK1 Phosphoglycerate kinase 
0.83  0.31  3.22  orf19.6220.4 orf19.6220.4 Ribosomal 60S subunit protein 
0.83  0.31  3.20  orf19.6515 HSP90 Essential chaperone 
0.84  0.32  3.16  orf19.979 FAS1 Beta subunit of fatty-acid synthase 
0.85  0.32  3.15  orf19.6367 SSB1 HSP70 family heat shock protein 
0.85  0.32  3.12  orf19.7600 FDH3 
Glutathione-dependent formaldehyde  
dehydrogenase 
0.85  0.32  3.12  orf19.6873 RPS8A Small 40S ribosomal subunit protein 
0.86  0.32  3.11  orf19.3642 SUN41 Cell wall glycosidase 
0.86  0.32  3.09  orf19.6854 ATP1 ATP synthase alpha subunit 
0.86  0.32  3.09  orf19.3911 SAH1 S-adenosyl-L-homocysteine hydrolase 
0.87  0.32  3.08  orf19.4980 HSP70 Putative hsp70 chaperone 
0.88  0.33  3.04  orf19.3354 orf19.3354 
structural constituent of ribosome activity  
and 90S preribosome 
0.88  0.33  3.04  orf19.3192 STI1 
Protein that interacts with Cdc37 and  
Crk1 in two-hybrid 
0.89  0.34  2.98  orf19.1891   Vacuolar aspartic proteinase 
0.90  0.34  2.97  orf19.4952.1 orf19.4952.1 FK506 binding, Hsp70 protein binding 
0.90  0.34  2.97  orf19.5285 PST3 Putative flavodoxin 
0.91  0.34  2.93  orf19.7080 LEU2 Isopropyl malate dehydrogenase 
0.91  0.34  2.92  orf19.974 ROT2 Alpha-glucosidase II 
0.93  0.35  2.88  orf19.2156 NAG1 Glucosamine-6-phosphate deaminase 
0.93  0.35  2.88  orf19.6312 RPS3 Ribosomal protein S3 
0.93  0.35  2.88  orf19.4716 GDH3 NADP-glutamate dehydrogenase 
0.93  0.35  2.86  orf19.4149.1 orf19.4149.1 
Protein component of the small (40S)  
ribosomal subunit 
0.93  0.35  2.85  orf19.5007 ACT1 Actin 
0.94  0.35  2.85  orf19.3572.3 orf19.3572.3 Ribosomal 60S subunit protein L31B 
0.94  0.35  2.84  orf19.7015 RPP0 Putative ribosomal protein 
0.94  0.35  2.84  orf19.2435 MSI3 Essential HSP70 family protein 
0.94  0.35  2.82  orf19.3499 orf19.3499 Secreted potein 
0.95  0.36  2.81  orf19.5225.2 RPL27A Ribosomal protein L27 
0.95  0.36  2.80  orf19.822 HSP21 Small heat shock protein 
0.95  0.36  2.80  orf19.5201.1 orf19.5201.1 
Has domain(s) with predicted enzyme  
inhibitor activity 
0.95  0.36  2.80  orf19.1064 ACS2 Acetyl-CoA synthetase 
0.95  0.36  2.80  orf19.251 GLX3 Glutathione-independent glyoxalase 
0.95  0.36  2.79  orf19.7585 INO1 Inositol-1-phosphate synthase 
0.96  0.36  2.78  orf19.3590 IPP1 Putative inorganic pyrophosphatase 
0.96  0.36  2.77  orf19.5466 RPS24 Predicted ribosomal protein 
0.97  0.36  2.76  orf19.4135 PRC2 Putative carboxypeptidase 
0.97  0.36  2.75  orf19.1409.1 orf19.1409.1 Ribosomal 60S subunit protein L22B 
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0.97  0.37  2.74  orf19.5645 MET15 
O-acetylhomoserine O-acetylserine  
sulfhydrylase 
0.98  0.37  2.73  orf19.542 HXK2 Hexokinase II 
0.98  0.37  2.73  orf19.6745 TPI1 Triose-phosphate isomerase 
0.98  0.37  2.72  orf19.953.1 COF1 Putative cofilin 
0.98  0.37  2.71  orf19.3765 RAX2 Plasma membrane protein 
0.98  0.37  2.71  orf19.734 GLK1 Putative glucokinase 
0.98  0.37  2.71  orf19.4490 RPL17B Ribosomal protein L17 
0.99  0.37  2.70  orf19.4290 TRR1 Thioredoxin reductase 
0.99  0.37  2.69  orf19.3997 ADH1 Alcohol dehydrogenase 
0.99  0.37  2.69  orf19.2347 MNN2 Alpha-1,2-mannosyltransferase 
1.00  0.37  2.67  orf19.3374 ECE1 Hypha-specific protein 
1.01  0.38  2.64  orf19.3789 RPL24A Predicted ribosomal protein 
1.01  0.38  2.64  orf19.4755 KEX2 Subtilisin-like protease 
1.02  0.38  2.62  orf19.2060 SOD5 Cu and Zn-containing superoxide dismutase 
1.02  0.38  2.62  orf19.3324 TIF Translation initiation factor 
1.02  0.38  2.61  orf19.5968 RDI1 Putative rho GDP dissociation inhibitor 
1.03  0.39  2.59  orf19.1789.1 LYS1 Saccharopine dehydrogenase  
1.03  0.39  2.58  orf19.657 SAM2 S-adenosylmethionine synthetase 
1.04  0.39  2.56  orf19.5996.1 RPS19A Putative ribosomal protein S19 
1.04  0.39  2.56  orf19.2864.1 RPL28 Putative ribosomal protein 
1.04  0.39  2.56  orf19.5112 TKL1 Putative transketolase 
1.05  0.39  2.55  orf19.6202 RBT4 Pry family protein 
1.05  0.39  2.55  orf19.1665 MNT1 Alpha-1,2-mannosyl transferase 
1.05  0.39  2.54  orf19.3294 MBF1 Putative transcriptional coactivator 
1.05  0.39  2.53  orf19.789 PYC2 Putative pyruvate carboxylase 
1.07  0.40  2.50  orf19.2841 PGM2 Ortholog of S. cerevisiae Pgm2 
1.07  0.40  2.49  orf19.1153 GAD1 Putative glutamate decarboxylase 
1.08  0.40  2.48  orf19.7611 TRX1 Thioredoxin 
1.08  0.41  2.47  orf19.2452 orf19.2452 Protein of unknown function 
1.08  0.41  2.46  orf19.437 GRS1 Putative tRNA-Gly synthetase 
1.09  0.41  2.45  orf19.4393 CIT1 Citrate synthase 
1.09  0.41  2.45  orf19.5964 ARF2 Putative ADP-ribosylation factor 
1.09  0.41  2.44  orf19.4309 GRP2 Methylglyoxal reductase 
1.10  0.41  2.42  orf19.6385 ACO1 Aconitase 
1.11  0.42  2.39  orf19.7048.1 RPS28B Putative ribosomal protein S28B 
1.12  0.42  2.39  orf19.5830 LHS1 Protein similar to S. cerevisiae Hsp70p 
1.12  0.42  2.38  orf19.3226 orf19.3226 
In intracellular sterol transport and  
extracellular region 
1.12  0.42  2.38  orf19.3014 BMH1 Sole 14-3-3 protein in C. albicans 
1.13  0.42  2.37  orf19.4899 GCA1 
Extracellular/plasma membrane-associated  
glucoamylase 
1.13  0.42  2.36  orf19.2937 PMM1 Phosphomannomutase 
1.13  0.42  2.35  orf19.4193.1 RPS13 
Putative ribosomal protein of the small  
subunit 
1.15  0.43  2.33  orf19.5741 ALS1 Cell-surface adhesin 
1.15  0.43  2.32  orf19.2622 YPT31 Resistance to toxic ergosterol analog 
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1.16  0.44  2.29  orf19.6906 ASC1 40S ribosomal subunit similar to G-beta  
1.16  0.44  2.29  orf19.6327 HET1 Putative sphingolipid transfer protein 
1.18  0.44  2.25  orf19.4336 RPS5 Ribosomal protein S5 
1.19  0.45  2.23  orf19.4602 MDH1-1 Predicted malate dehydrogenase precursor 
1.23  0.46  2.17  orf19.2677 orf19.2677 Putative GPI transamidase component 
1.23  0.46  2.17  orf19.4152 CEF3 Translation elongation factor 3 
1.24  0.46  2.16  orf19.2028 MXR1 Putative methionine sulfoxide reductase 
1.24  0.47  2.15  orf19.4150 orf19.4150 Putative glutaredoxin 
1.25  0.47  2.14  orf19.1946 orf19.1946 Aldose 1-epimerase-related protein 
1.25  0.47  2.13  orf19.2769 orf19.2769 Putative protease B inhibitor 
1.25  0.47  2.13  orf19.1671 UTR2 Putative GPI anchored cell wall glycosidase 
1.26  0.47  2.11  orf19.7417 TSA1 TSA/alkyl hydroperoxide peroxidase C  
1.27  0.48  2.10  orf19.6975 YST1 Ribosome-associated protein 
 
Table S-3 MS data of SPE experiment 
Accession Description ΣCoverage Σ# Peptides Σ# PSMs 
orf19.3374 ECE1 88.56 54 256 
 
Sequence # PSMs Accessions Modifications 
  SIIGIIMGILGNIPQVIQIIMSIVKAFKGNKR 50 orf19.3374   
  SIETVGIENAAQIVSER 24 orf19.3374   
  DGVPDVGLNLVANAPR 22 orf19.3374   
  SIIGIIMGILGNIPQVIQIIMSIVKAFKGNKR 18 orf19.3374 M21(Oxidation) 
  DGANDDVANAVVRLPEIVA 12 orf19.3374   
  DISSLIEEYFGKA 11 orf19.3374   
  VATGVQQSIENAK 10 orf19.3374   
  SAESALKDSQPVK 6 orf19.3374   
  RVATGVQQSIENAK 6 orf19.3374   
  NAAQIVSER 5 orf19.3374   
  DGANDDVANAVVRLPEIVAR 5 orf19.3374   
  LVANAPR 4 orf19.3374   
  TGVQQSIENAK 4 orf19.3374   
  AVDTAMTSVASTK 4 orf19.3374 M6(Oxidation) 
  DGANDDVANAVVR 4 orf19.3374   
  DISSLIEEYFGK 4 orf19.3374   
  DGLEDFLDELLQRLPQ 4 orf19.3374   
  GVPDVGLNLVANAPR 4 orf19.3374   
  SAESALKD 3 orf19.3374   
  EDIDSVVAGIIADMPFVVR 3 orf19.3374   
  NVFDGVSETVQQAKR 3 orf19.3374   
  DGLEDFLDELLQRLPQL 3 orf19.3374   
  VATGVQQSIENAKR 2 orf19.3374   
  SIIGIIMGILGNIPQVIQIIMSIVKAFKGNK 2 orf19.3374 M21(Oxidation) 
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Accession Description ΣCoverage Σ# Peptides Σ# PSMs 
  SIVKAFKGNK 2 orf19.3374   
  VGLNLVANAPR 2 orf19.3374   
  VVRLPEIVAR 2 orf19.3374   
  VPDVGLNLVANAPR 2 orf19.3374   
  ITRSAESALKDSQPV 2 orf19.3374   
  EDIDSVVAGIIADMPF 2 orf19.3374 M14(Oxidation) 
  DGANDDVANAVVRLPEIV 2 orf19.3374   
  DVAPAAPAAPADQAPTVPAPQEFNTAITK 2 orf19.3374   
  DVAPAAPAAPADQAPTVPAPQEFNTAITKR 2 orf19.3374   
  DAGSVALSNLIKK 2 orf19.3374   
  EFNTAITKR 1 orf19.3374   
  SAESALKDSQPV 1 orf19.3374   
  SAESALKDSQPVKR 1 orf19.3374   
  AVDTAMTSVASTK 1 orf19.3374   
  GIENAAQIVSER 1 orf19.3374   
  RSAESALKDSQPV 1 orf19.3374   
  DGANDDVANAVVRL 1 orf19.3374   
  ETVGIENAAQIVSER 1 orf19.3374   
  DGLEDFLDELLQRL 1 orf19.3374   
  ANDDVANAVVRLPEIVA 1 orf19.3374   
  DGANDDVANAVVRLPEI 1 orf19.3374   
  DGVPDVGLNLVANAPRLIS 1 orf19.3374   
  EDIDSVVAGIIADMPFVVR 1 orf19.3374 M14(Oxidation) 
  DGLEDFLDELLQRLPQLI 1 orf19.3374   
  DGLEDFLDELLQRLPQLIT 1 orf19.3374   
  DGANDDVANAVVRLPEIVARVA 1 orf19.3374   
  DGLEDFLDELLQRLPQLITR 1 orf19.3374   
  
NKREDIDSVVAGIIADMPFVVRAVDTAMTSVASTKRDGAND
DVANAVVRLPEIVA 
1 orf19.3374 M17(Oxidation)M28(Oxi
dation) 
  GIIADMPFVVR 1 orf19.3374 M6(Oxidation) 
  RVATGVQQSIENA 1 orf19.3374   
  EDIDSVVAGIIADMPFV 1 orf19.3374 M14(Oxidation) 
  LISNVFDGVSETVQQAKR 1 orf19.3374   
  STKRDGANDDVANAVVRLPEIVAR 1 orf19.3374   
orf19.6928 SAP9  5.88 3 23 
 
Sequence # PSMs Accessions Modifications 
  GESKDDLSPEDDSNPR 11 orf19.6928   
  RGESKDDLSPEDDSNPR 10 orf19.6928   
  NERSFGHGTGVKLNE 2 orf19.6928   
orf19.1327 RBT1  4.02 3 21 
 
Sequence # PSMs Accessions Modifications 
  EAEIANKDGTIEK 16 orf19.1327   
  ELDEFEELSNDGVTHS 3 orf19.1327   
  ELDEFEELSNDGVTH 2 orf19.1327   
orf19.3004 orf19.3004  12.44 3 6 
 
Sequence # PSMs Accessions Modifications 
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Accession Description ΣCoverage Σ# Peptides Σ# PSMs 
  KNVIDPASLKEGSAEEEQKDK 4 orf19.3004   
  KNVINLSNFIETPS 1 orf19.3004   
  KNLFDLTKFQQSGQPI 1 orf19.3004   
orf19.5542 SAP6  6.46 2 5 
 
Sequence # PSMs Accessions Modifications 
  SLVDPDDPTVESK 3 orf19.5542   
  GPVAVKLDNEIITY 2 orf19.5542   
orf19.1597 ABG1  6.25 1 4 
 
Sequence # PSMs Accessions Modifications 
  DKQSDNENDAEIEQEIER 4 orf19.1597   
orf19.2452 orf19.2452  3.13 1 4 
 
Sequence # PSMs Accessions Modifications 
  SSSDTTTSGTTIH 4 orf19.2452   
orf19.6741 orf19.6741  3.13 1 3 
 
Sequence # PSMs Accessions Modifications 
  DGVGSKMVSINPR 2 orf19.6741   
  DGVGSKMVSINPR 1 orf19.6741 M7(Oxidation) 
orf19.3642 SUN41 2.63 1 2 
 
Sequence # PSMs Accessions Modifications 
  EDCDKTSFHGH 2 orf19.3642   
orf19.5585 SAP5  5.50 1 1 
 
Sequence # PSMs Accessions Modifications 
  LFLEFTPSEFPVDETGRDGDVDK 1 orf19.5585   
orf19.1442 PLB4.5  2.28 1 1 
 
Sequence # PSMs Accessions Modifications 
  DTQNNDEKEEFIGVVR 1 orf19.1442   
orf19.1426 orf19.1426  2.12 1 1 
 
Sequence # PSMs Accessions Modifications 
  PTFDLVYERTPTLEV 1 orf19.1426   
orf19.894 orf19.894  1.15 1 1 
 
Sequence # PSMs Accessions Modifications 
  ALLRVQSS 1 orf19.894   
orf19.1490 MSB2  1.06 1 1 
 
Sequence # PSMs Accessions Modifications 
  YQQENEITPADNIDK 1 orf19.1490   
orf19.3681 orf19.3681 1.03 1 1 
 
Sequence # PSMs Accessions Modifications 
  ADMVVDAID 1 orf19.3681 M3(Oxidation) 
orf19.663 GIN4  0.89 1 1 
 
Sequence # PSMs Accessions Modifications 
  IRKFNTILPKHE 1 orf19.663   
 
 
 
  Supplements 
80 
 
Table S-4 Sample loading list of patients´sera 
Addition of 1st. Ab.(dilution 1:1000 in blocking solution 0,5% casein in TBS, 
100µl /well); incubate for 30min at RT 
  1 2 3 4 5 6 7 8 9 10 11 12 
A A91 A105 E43 E44 E97 A B C D E F G 
B A91 A105 E43 E44 E97 A B C D E F G 
C H I J P56 P083 P091 P112 P129 P279 P283 P289 P413 
D H I J P56 P083 P091 P112 P129 P279 P283 P289 P413 
E P451 P1127 P1205 P1255 P1386 P2649 P2949 NC1 NC2 NC3 NC4 NC5 
F P451 P1127 P1205 P1255 P1386 P2649 P2949 NC1 NC2 NC3 NC4 NC5 
G NC6 NC7 NC8 NC9 NC10 G1 G2 G3 G4 G5 G6 G7 
H NC6 NC7 NC8 NC9 NC10 G1 G2 G3 G4 G5 G6 G7 
 
Table S-5 TMT6plex sample labeling list 
TMT-Ratio 
(Yeast/Hypha) sample 
127/126 2-yeast/1-Hypha 
129/126 3-yeast/1-Hypha 
131/126 4-yeast/1-Hypha 
127/128 2-yeast/2-Hypha 
129/128 3-yeast/2-Hypha 
131/128 4-yeast/2-Hypha 
127/130 2-yeast/3-Hypha 
129/130 3-yeast/3-Hypha 
131/130 4-yeast/3-Hypha 
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Abbreviation 
2D two dimensional 
A. Aspergillus 
A.P. acute pancreatitis 
ACN acetonitrile 
AGC automatic gain control 
ALS agglutinin-like sequence  
amu unified atomic mass unit, dalton 
APC antigen-presenting cell 
ATP adenosine triphosphate 
BCR B cell receptor  
°C celsius degree 
C. Candida 
CGD Candida genome database 
CHAPS 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate 
cm centimeter 
CO2 carbon dioxide 
compl. complement 
COPD chronic obstructive pulmonary disease 
CWP cell-wall protein 
Cys cystein 
Da dalton 
DDA data-dependent acquisition 
DP dolichol phosphate  
DPGS dolichol phosphate glucose synthase  
DPMS dolichol phosphate mannose synthase  
DTT dithiothreitol 
EDTA ethylenediaminetetraaacetic 
ELISA enzyme-linked immunosorbent assay 
ER endoplasmic reticulum  
ESI electrospray ionization  
et al. and others 
etc. and so forth 
Fas fasciclin 
FDR false discovery rate 
FWHM full width at half maximum 
g gram 
GE gel electrophoresis 
GO gene ontology 
GPI glycosylphosphatidylinositol 
h hour 
HCCA α-cyano-4-hydroxycinnamic acid 
HCD Higher-energy collisional dissociation 
HIV human immunodeficiency virus 
  Abbreviation 
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HRP horseradish peroxidase 
i.e. that is 
IC invasive candidiasis 
IgG Immunoglobulin G 
IPG Immobilized pH gradient 
k kilo 
K lysine 
kV kilo volt 
L liter 
LC liquid chromatography 
M molecular mass marker proteins 
m meter 
MALDI-TOF matrix-assisted laser desorption/ionization-time of flight 
Met methionine 
mg milligram 
MHC major histocompatibility complex 
min minute 
mM millimolar 
MOPS 3-(N-morpholino)propanesulfonic acid 
MR mannose receptor  
MS mass spectrometry 
ms millisecond 
MWCO molecular weight cut-off 
NL non-linear 
nm nanometer 
OD optical density 
OP operation 
OST oligosaccharyl transfer complex  
PA polyacrylamide 
PAMP pathogen-associated molecular pattern 
PAS periodic acid-schiff 
PBS phosphate buffered saline 
PC proprotein convertase 
PES polyethersulfone 
Pir       proteins with internal repeats 
PLGS proteinlynx glolbal server 
ppm parts per million 
PRR pattern recognition receptor 
PSM peptide spectral match 
PTM post-translational modification 
PVDF polyvinylidene difluoride 
R arginine 
RFP red fluorescent protein 
rpm rotations per minute 
RSLC rapid separation liquid chromatography 
SC systemic candidasis 
  Abbreviation 
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SDS sodium dodecyl sulfate 
SERPA serological proteome analysis 
SIRS systemic inflammatory response syndrome 
SPC subilisin-like Proprotein Convertase 
SPE solid phase extract 
Spp. species pluralis 
TBS tris buffered saline 
TCA trichloroacetic acid  
TCR T-cell receptor 
TFA trifluoracetic acid 
TFE trifluoroethanol 
TLR toll-like receptor 
TMB tetramethylbenzidine 
TMT tandem mass tag 
UPLC ultra performance liquid chromatography 
UV ultraviolet 
V voltage 
v/v volume/volume 
Vhs voltage hours 
W watt 
w/v weight/volume 
wt wild type 
YNB yeast nitrogen base 
YPD yeast Nijmegen breakage syndrome 
μL microliter 
μm micrometre 
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